Other,-916
Other,0.00001
Other,0.0001
Other,0.001
Other,0.003
Other,0.007
Other,0.014
Other,0.02
Other,0.021
Other,0.029
Other,0.32
Other,0.46
Other,0.52
Other,0.84
Other,1
Other,4
Other,4.71
Other,10.1
16,13
Other,18.791
16,20
16,40
Other,42
16,50
77,77
Other,408
Other,700
Other,1984
9398,9398
Adulthood,0-5Years
16,100000Person-years
16,1000Patients
16,100Patients
10-fold,10-foldCross-validation
16,10Mg/kg
16,10Percecnt
10-year,10-yearBreastCancerSurvival
16,11BreastRadiologists
16,11Days
16,11HereditaryBreastCancerGenes
16,120BreastCancerPatients
16,120Patients
Other,12-15Percecnt
Users,12331Non-nsaidUsers
Users,12331Users
Other,12404Patients
Other,125DogSeraSamplesIncluding75MammaryTumourSera
16,12EventsAmong121Patients
16,12SampledWomen
Other,131Percecnt
Other,133BreastCancerCases
Other,133Controls
Other,13-hDailyOvernightFast
16,13Percecnt
16,13PercecntOfDeaths
Other,1444Women
Other,147Patients
16,15Percecnt
160,160Patients
16,16PrimaryBreastCancers
Other,1722Comments
Subgroup,17MillionPeople
Global,17MillionPeopleWorldwide
16,17Years
Other,182Percecnt
186,186Pathology-provenS
186,186S
Young,193FemaleParticipants
Adulthood,195Years
Other,1973To2014
Alpha,1H
Other,1Year
Adulthood,1YearTo5Years
Other,2=
Other,2009-13
Other,2012AtBreastClinicOfPortugueseInstituteOfOncologyInPorto
16,20BreastCancerPatients
Actual,20PercecntIncreasedRiskOfBreastCancerAmongCurrentHormonalContraceptionUsers
16,21Months
16,22Deaths
16,22Patients
16,23Studies
Adulthood,2-3Years
Germline,244GermlinePathogenicVariants
Germline,244GermlineVariants
Other,252Percecnt
16,25CaseReports
Other,282Patients
Other,2921Posts
Mood,2-groupRandomizedControlTrial
Other,2IndependentCohorts
16,30DoublingTimesNecessary
Alpha,30TBreastMagneticResonanceImagingExaminations
PCOS,32620MatchedPatientsWithoutPcos
Adulthood,35-64Years
Other,38Months
Young,38-year-oldFemale
Factors,3ClinicopathologicalFactors
ST-2,3GroupsBasedOnTertiarySolubleSt-2Level
Other,3-timeAssessments
16,40Percecnt
Other,414Percecnt
Other,417Percecnt
Other,4248BreastCancerPatients
Other,428BreastCancerPatients
Other,42Patients
Other,464Percecnt
Adulthood,476Years
Other,481Women
Adulthood,48Years
CEDM,49CedmCasesCollectedFromMayoClinic
Other,49Patients
Other,4Categories
Other,4Domains
Other,505Percecnt
Other,505PercecntOfAnalyzedCases
16,50PercecntRelapsedTissues
16,510YearsAfterSurgery
Other,51Days
Other,51Patients
Survivors,535941Survivors
Other,54BreastCancerPatients
Other,56Patients
Other,57PercecntOfPatients
Other,5CmLess
Other,5-khzFrequencies
16,5Of10Patients
Contribution,5-yearResultsOfPhase3Isg23-01Trial
Other,5Μl
Other,606Percecnt
Adulthood,6084Years
Mood,60ControlPatients
Adulthood,62Years
Other,643Percecnt
Conflict,643PercecntWithSignificantDifferenceBetweenWhites
Other,65Patients
Young,65-year-oldFemale
Other,67BreastCancerSamplesFrom66Patients
Other,68Percecnt
Other,6Months
Japanese,7051UnselectedBreastCancerPatientsOfJapaneseAncestry
Caregiver,70-year-oldWoman
Other,72Months
Other,731Percecnt
Caregiver,73-yearOldWomanPresentingWithLeftBreastLumpClinicallyIndeterminate
Other,7581StageI/iiaCases
Other,768PercecntSamplesWithOverexpressionIn76Cases
Other,773Percecnt
77,77Patients
Other,8155Patients
Other,845Percecnt
Other,84Patients
Other,876Percecnt
Other,876PercecntRespectively
FFDM,89FfdmCases
Other,902Percecnt
Other,905Percecnt
16,90Percecnt
16,90PercecntOfPatientsWithRecurrence
93,93Percecnt
Postmenopausal,952PercecntOfthePostmenopausalWomen
Other,95PercecntConfidenceIntervals
Other,976PercecntSensitivity
Other,992Percecnt
Other,992PercecntOfCases
Other,99Percecnt
Positivity,99PercecntAccuracyInTermsOfClassification
European,9EuropeanCountries
Alpha,a
Aberrances,aberrances
DNA,aberrantDnaMethylation
Other,aberrantlyExpressed
Other,able
16,about30Percecnt
Accumulation,abstractDataOnTheirClinicalCharacteristics
Access,Access
Other,access
Other,accessToEarlyDiagnosis
Other,accessToReceptorAnalysesInCytosolAtDiagnosis
Other,accomplished
Other,accumulatingResults
Positivity,accuracy
Positivity,accuracyScores
Subtypes,accurateDiagnosisOfBreastCancerSubtypes
Other,accurateMethod
Township,accurateViewOfStateOfMetastasesToAxillaryLymphNodes
Other,achieved
HER2,achievedForHer2Status
Complex,acid
Mood,activatedComplex
Adult,active
Adult,activeNon-participants
Activities,activities
Conflict,activity
Conflict,activityOfCellProliferationInBreastCancerCells
Actual,actualIncidence
Acupuncture,Acupuncture
Mood,acuteDangerToMother
Disease,AD
Other,added
Amplification,addition
Other,additionalAnalyses
Output,additionalIndicator
Entry,additionalInformation
Mood,additionalLocalControl
Other,additionallyCorrelated
Revealed,additionallyRevealed
Other,adherence
Other,adherenceToEhtAmongBreastCancerPatients
Other,adherenceToRecommendationWith95PercecntConfidenceIntervals
Protein-1,adhesionProtein-1
Other,adjacentNon-tumorousTissues
Hazard,adjustedHazardRatio
Intensity,adjustedProportion
Factors,adjustingForPotentiallyConfoundingFactors
Anastrozole,adjuvantAnastrozole
Other,adjuvantEndocrineHormonalTherapy
Other,administered
Neoadjuvant,administrationOfNeoadjuvant
AD,adPatients
Adulthood,adulthood
Testing,advancedAnalysis
Disease,advancedBreastCancer
Base,advancedBreastCancerBearingMutations
Base,advancedBreastCancerBearingMutationsInGenesInvolvedInPi3k/ark/mtorSignalingPathway
Other,advancedDiagnosticImaging
Other,advancedStage
Other,advances
Other,advancesInBreastCancerDiagnosis
Advantage,advantage
Technique,advantageOfHigh-throughputLuminexTechnique
Other,advantages
Conflict,adverseEventsExceptDegreeI-iiBleeding
Other,affected
Subset,after6Months'TherapySignificantlyHigherIn3rdTertiaryGroup
Evolve,age
Testing,age-basedScreeningPrograms
Evolve,ageGroups
Systematic,age-matchedSystematicRandom-samplingMethod
Other,agents
Evolve,ageOfTreatmentMethods
Biocharacter,agonistic/antagonisticBiocharacter
Mood,agreement
Purpose,aim
Other,aimed
Disease,AION
Number,alarm
Other,alarmingLevelGlobally
Water,alcoholConsumption
Other,alexnetModels
Other,algorithm
Sensitive,alive
Other,all
Other,allBreastCancerPatients
Almaty,almatyCity
Phenotype,alongsideRoutineMethodEmployedOnTexture
Other,alreadyWell-established
Other,alsoAssessed
Other,alsoAssessedByQrt-pcr
Formed,alsoShaped
Utilized,alsoUsed
Other,alteredInHumanBreastCarcinoma
Testing,alternativeContrast-enhancedScreeningTools
Other,alternativeMeans
Other,alternativeOption
Other,alternativeToFrozenSections
AMD3100,AMD3100
Disease,amenorrhea
Focus,amongThemNewlyIdentifiedInStudy
Intensity,amount
Other,amplifications
Other,an
Other,analysed
Other,analyses
Other,Analysis
Testing,analysis
Testing,analysisInvestigate
Contribution,analysisMayAid
Testing,analysisOfLncrnaExpressionProfiles
Other,analyzed
Other,analyzedBeforeAnd
Other,analyzedRetrospectively
Care,analyzedtheOperationTime
Other,analyzing
Chemical,anastrozole
Other,andfemales
Anemia,Anemia
Annexin,annexinVStaining
Other,annualMammographyAssociatedWithEchography
Radiotherapy,anthracyclineChemotherapyAgents
Other,Anthracyclines
Other,anti-apoptoticEffectsOfEstradiol
Other,antibodies
Other,antibody-anchoredMagneticBeads
Strategy,antibody-basedStrategy
Conjugates,antibodyDrugConjugates
Antibody,antibodyPanel
Other,anticipated
Hazard,anticipatedOutcome
Finding,antigenIdentification
MiR-34s,anti-oncogenicRegulationOfMir-34s
Conjugate,anti-ronMonoclonalAntibodyZt/g4-drugMonomethylAuristatinEConjugate
Conflict,anti-tumorActivity
Disease,anxiety
Apoptosis,apoptosis
Entry,appearance
Other,Applications
Other,applied
RL,appliedTo70PatientsWithUnilateralRl
Other,approaches
Other,appropriateDiagnosisOfBreastCancer
Other,appropriateInterpretation
Other,appropriateSequencing
Other,approximately75PercecntOfBreastCancers
Aptamer,aptamerMf3
Other,archivedFormalin-fixedParaffin-embeddedTissue
Platform,area
Discovery,areaOfResidence
Other,areas
Platform,areaUnderReceiverOperatingCharacteristicCurve
Utilized,areUsed
Other,arms
Contribution,aromataseInhibitor-inducedBoneLoss
Restoration,article
Intensity,asInCaseShouldAlwaysKeptInMindSpeciallyInHighVolumeCenters
Other,aspects
Aspiration,aspirationCytology
Purpose,aspirinUse
Description,asResultAreUsed
Food,assay
Other,assessed
Entry,assessedinclusionCriteriaForEnrolment
Other,assessedPreoperatively
Interference,assessment
Interference,assessmentOfImpactOfAdvancesInDiagnosisOfPatientsWithBreastCancer
Other,assessments
Other,associated
Hazard,associatedWithBreastCancerRisk
Intensity,associatedWithPfsAlthoughAtExtent
Subgroup,association
Danger,associationBetweenNsaidsExposureInFemalePatientsWithAd
Purpose,associationBetweenPost-diagnosisLow-doseAspirinUse
Purpose,associationBetweenPost-diagnosisUseOfLow-doseAspirin
Testing,associationBetweenPreviousCervicalCancerScreeningInBreastCancerScreening
Race/color,associationBetweenRace/colorInWomenWithBreastCancer
Subgroup,associationBetweenTumorUptakeInInvasiveDuctalCarcinoma
Subgroup,associationOfPcdh10Methylation
Subgroup,associationOfToll-likeReceptor6WithBreastCancerInSaudiArabianWomen
Associations,Associations
Other,associations
Locoregional,associationsOfFactorsWithLocoregionalAtDiagnosis
Conflict,associationsOfPhysicalActivityInGlobalHealthInBreastCancerSurvivors
Focus,associationStudy
Asymptomatic,asymptomaticWomen
Restoration,at25HPost-injectionGreaterInTumorBedThanInKidneyRespectively
Conflict,atEndOfFollow-upClassifiedRegardingTheirAdherenceToRecommendationsForCancerPrevention
Membrane,atrophiedVaginalMucosa
Other,attempted
Care,attention
Atypia,atypia
Other,AUC
Other,australianSynchrotron
Authors,authors
Autoantibodies,autoantibodies
Disease,autoimmuneDiseases
Number,automatedAnalysisOfClinicallyRelevantHistopathologicFeature
Finding,automaticIntraoperativeIdentificationOfBreastCancerMargins
Other,autonomyOfPatients
Testing,autopsyStudies
Other,available
Conflict,availableContrastAgents
Odds,average
Odds,averageOf425±496Ctcs/2Ml
Sites,averageOfFiveInvolvedSites
Other,avoidance
Other,awareness
Interval,axillaryClearance
Axillary,axillaryDissection
Focus,axillaryLymphNode
Focus,axillaryLymphNodeOfBreastCancerPatients
Axillary,axillarySurgery
AYAs,AYAs
Interference,backgroundParenchymalEnhancement
Other,backgroundTrastuzumab
Subset,baGroup
Chemical,baicalin
Base,balb/cNudeMiceBearing
Susceptibility,barcodeMode
Capillaries,bareCapillaries
Interference,barrierFunction
Other,Barshi
Number,base
Other,based
Benchmark,baselineBpeLevels
Baseline,baselineSolubleSt-2Level
Baseline,baselineSt-2Level
Base,basis
Network,bayesianNetworkMeta-analysis
Other,Belgium
Benchmark,benchmarkMethod
Other,benign
Other,benignBreastLesions
Contribution,bestAvailableEvidence
Contribution,bestChancesOfCure
Contribution,bestStandardTreatmentRegimenAvailable
Other,better
Focus,betterAccessToAtertiaryCancerCenter
Positivity,betterDiagnosticAccuracyThanFfdm
OS,betterOs
Other,betterOutcomes
Restoration,betterOutcomeWithGoodNegativePredictiveValue
Other,betterPrognosis
Other,betterResults
Will,betterUnderstanding
16,betterUnderstandingOfRisksAssociatedWithM
Other,bevacizumab-relatedCardiotoxicity
Other,bilateralBreastLumps
Mastectomies,bilateralMastectomies
Other,bilateralSalpingo-oophorectomy
Mastectomies,bilateralTotalMastectomies
Isolation,binaryLogisticRegressionModels
Binding,binding
Binding,bindingToBreastCancerCellsInVitro
Biocharacter,biocharacter
Testing,bioimpedanceAnalysis
Subtypes,biologicalSubtypes
Other,biomarker
Other,biomarkers
Other,bio-metal-organicFrameworkCoated
Biopsy,biopsy
Black,blackWomen
Cohort,blood
Cohort,bloodSamples
Other,BMI
Entry,body
Intensity,bodyMassIndex
Entry,bodyWeight
Distance,boneDensity
Disease,boneLoss
Other,bone-modulatingAgents
BPE,BPE
Levels,bpeLevels
Brain,brainMetastases
Disease,brainMetastasis
Gene,BRCA1
Gene,BRCA1/2
Other,brca-associatedCancers
Other,BRCAs
Other,breast
Disease,breastCancer
Cohort,breastCancerAged
Other,breastCancerCases
Spread,breastCancerCellInvasion
Other,breastCancerCells
Learning,breastCancerClassification
Other,breastCancerConfinedWithinMammaryDuctsSurrounded
Mood,breastCancerControl
Mood,breastCancerControlEfforts
Mood,breastCancerControlEffortsForIdentification
Discovery,breastCancerDetectionMethod
Disease,breastCancerDiagnosis
Genes,breastCancerGenes
Cytology,breastCancerGenetics
Kenya,breastCancerGeneticsInKenya
Other,breastCancerGrading
Other,breastCancerIncidence
Other,breastCancerMcf-7
Other,breastCancerMetastasis
Other,breastCancerModels
Subtypes,breastCancerMolecularSubtypes
Other,breastCancerPatients
Other,breastCancerPatientsSerum
2-Jan,breastCancerPatientsWith1-2PositiveSlnspatientsWithBreastCancer
Bromide,breastCancerPatientsWithParticularReferenceToOverallSurvivalAndrecurrenceFreeSurvivalAmongBreastCancerPatients
Other,breastCancerRelapse
Hazard,breastCancerRisk
Disease,breastCancers
Testing,breastCancerScreening
Testing,breastCancerScreeningProgramme
10-year,breastCancer-specific10-yearSurvival
Disease,breastCancerStaging
Other,breastCancerStudies
Other,breastCancerSubtypesa
Other,breastCancerTherapy
Other,breastCancerTissueMicroarrayWithAccessToReceptorAnalyses
Other,breastCancerTissues
Disease,breastCancerWisconsin
Adulthood,breastCancerYoungerThan45Years
Disease,breastCarcinoma
Other,breastConservation
Testing,breastExamination
Other,breastImagingModality
Other,breastMetastases
Other,breastMetastasis
Neuromas,breastNeuromas
Testing,breastScreening
Survival,breastSurvival
Disease,breastTumor
Other,breastTumorMicroenvironment
Other,breastTumorProgression
Cell,breastTumorProgressionIncludingTumorCellGrowth
Other,broadcasted
Other,broadDifferentialDiagnosis
Purpose,broadUseToPatients
Bromide,bromideAssay
Other,bronchoalveolarCarcinomaUnrelatedToKnownMetastaticBreastCancer
Other,bt549Cells
Expert,bulkyHighlyTechnical
Restoration,byDevelopmentOfHybridomaTechnologyHaveProducedInManyLaboratories
Testing,byWhichObservedInNondestructiveWayThroughThermalAnalysis
16,C
Other,C1
CMIA,ca15-3ByCmia
Discovery,ca15-3Detection
Discovery,caDetection
Other,calculated
Other,caloricRestriction
Cell,canCategorized
Subtypes,canCategorizedIntoSubtypesOfLuminalA
Disease,cancer
Fibroblasts,cancerAssociatedFibroblasts
Restoration,cancerCareCenter
Restoration,cancerCareNetwork
Restoration,cancerCareSystems
Other,cancerCells
Mood,cancerControlPlanning
Entry,cancerCounseling
Conflict,cancerDeathAmongWomenWorldwide
Other,cancerDiagnosis
Fibroblasts,cancerFibroblasts
Disease,cancerGenomeAtlas
Other,cancerMolecularDiagnosis
Disease,cancer-relatedDeath
Disease,cancer-relateddeaths
Other,cancer-relatedDeathsAmongWomen
Cell,cancer-relatedEventsIncludingTumorCellMigration
Testing,cancerResearch
Hazard,cancerRiskPerception
Cell,cancerStemCellHypothesis
Susceptibility,cancerSusceptibilityGenes
Other,cancerTreatment
Cell,canClassified
Cell,canConsidered
Cell,canDiagnosed
Cell,canDifficult
Cell,canEasilyExtended
Cell,canEffectivelyTreatedByEndocrineTherapy
Cell,canExtended
Cell,canHeavilyInfluenced
Cell,canImportant
Cell,canImportantToDiagnosis
Cell,canIncluded
Cell,canIncludedInDifferentialDiagnosisOfMasses
Canines,canines
Other,canineTumours
Cell,canOnlyDiagnosedOnPresentationOfSymptoms
Cell,canStarted
Cell,canStartedAtVeryEarlyStage
Benchmark,canTherapeuticTargetForNextGenerationOfSerms
Cell,canUsed
Capabilities,capabilities
Cell,capacitance
Output,capacity
Third-line,capecitabineRegimenAsThird-lineTreatmentForAdvancedTriple-negativeBreastCancer
Capillaries,capillaries
Other,carbohydrateRestriction
Laser,carbonDioxideLaserTechnology
Disease,carcinogenesis
Disease,carcinoma
Disease,cardiacInjury
Cardiac,cardiacTroponins
Hazard,cardiotoxicRisk
Restoration,care
Restoration,careProvider
Hybrid,carrier
Caregiver,case
Focus,case-controlAssociationStudyForVariantsInCodingRegionsOf11HereditaryBreastCancerGenesIn7051UnselectedBreastCancerPatientsOfJapaneseAncestry
Spouse,caseOf68-year-oldCaucasianFemaleWithFamilyHistoryOfCancer
Caregiver,caseRecords
Other,Cases
Other,casesWithoutMetastasisOnDiagnosticImaging
Danger,cause
Other,causes
Contribution,ccsCoverage
CEDM,CEDM
Cell,Cell
Conflict,cellCycleArrestFollowedByMassiveCellDeath
Fertility,cellCycleRegulators
Spread,cellInvasion
Cell-killing,cell-killingEffect
Cell-killing,cell-killingEffectInTriple-negativeSubtypeMda-mb-231Cells
Cell,CellLines
Cell,cellMigration
Cell,cellProliferation
Other,Cells
Other,centralDenmarkRegion
Other,CGI
Description,challenge
Other,challengingProblem
Other,chances
Other,changes
Susceptibility,changesInHealthBehavioursAfterBreastCancerDiagnosis
Susceptibility,changesToIntimateIssuesIncludingSexualHealth
Other,chapter
Other,characteristics
Distance,characteristicsInsideTumors
Description,characterization
Other,characterized
Radiotherapy,chemotherapy
Radiotherapy,chemotherapyGroups
Radiotherapy,chemotherapyHormonalTreatment
Radiotherapy,chemotherapyRecommendations
Regimens,chemotherapyRegimens
Nonparticipation,chemotherapyResistance
Scans,chestCtScans
Other,Chi
Other,childbearingReasonsIncluding
Other,childHealth
Other,China
Chinese,chineseExpertGroup
Chinese,chinesePublic
Platinum,chlorambucilPlatinum
Resistance,choiceOfChemotherapyInBrca-associatedCancers
Cholecystectomy,Cholecystectomy
Disease,chorea
Disease,choreiformMovements
Chosen,chosen
Other,chronic
Interference,chronicDebilitatingLifelongComplication
CircRNAs,circRNAs
Circulating,circulatingSolubleRankl
Circulating,circulatingTumorCells
Other,clarify
Sensitive,classified
Other,classifiers
CLB-Pt-CLB,CLB-Pt-CLB
CLB-Pt-CLB,clb-pt-clbProdrug
Platform,clearcellPlatform
Distinct,clearEvidenceForbenefitsOfTanUsageInBreastCancerClassification
Other,clinicalBreastCancerTrials
Testing,clinicalBreastExamination
Conjugate,clinicalBreastExaminationCoupledAsPrimaryTool
Restoration,clinicalCare
Other,clinicalCharacteristics
Restoration,clinicalCharacteristicsOfCareOfBreastCancerPatients
Other,clinicalDepression
Nonparticipation,clinicalFeasibilityOfCtcIsolation
Other,clinicalOutcomesDiffer
Description,clinicalPicture
Other,clinicalPractice
Other,clinicalRecords
Other,clinicalSetting
Other,clinicalSettingOfPreviouslyVagueDiagnosisInImaging
Distinct,clinicalVariablesAmongDifferentGroups
Other,clinicalVisits
Other,clinicians
Other,clinico-epidemiologicalFeaturesOfBreastCancer
Other,clinicopathologicalCriteria
Other,clinico-pathologicalFeaturesOfMetastases
Hazard,clinico-pathologicalRiskFactors
Restoration,closedLoopStructure
Other,closelyAssociated
CMIA,CMIA
CNN,CNN
Accumulation,cnvData
CNVs,CNVs
Distinct,cnvsOfDifferentCancers
Other,coding
Co-existence,Co-existence
Focus,cohortStudy
Other,collapsing
Other,collected
Susceptibility,collectedFromElectronicHealthRecord
Signatures,collectedSignatures
Disease,collisionTumor
Conflict,collisionTumorWithBreastCancerMetastasis
Entry,colonyFormation
Axis,combination
Testing,combinedAnalysis
Membrane,combinedPanel
Other,common
Adult,commonAdultCancers
Other,commonCancer
Other,commonCancerTypes
Danger,commonCause
Danger,commonCauseOfMorbidity
Other,commonComplaint
Mood,commonEndocrineDisorder
Global,commonMalignancyWorldwide
Other,commonMalignantDisease
Other,commonMedications
Platform,commonPlatformForStakeholdersIncludingPolicymakers
Alpha,comorbiditiesThanSPatients
Other,compared
Apatinib,comparedBetween2GroupstheApatinib
Other,comparedBetweenMetastaticSlns
Other,comparedBetweenPremenopausalGroupsBetweenPcrGroups
Other,comparedToThoseWithPregestationalBreastCancer
Testing,comparison
Number,comparisonCohort
Actual,comparisonOfPredictedIncidenceOfBreastCancerWithActualIncidenceInPopulation-basedStudies
Comparisons,Comparisons
Comparisons,comparisons10-yearSurvival
Testing,comparisonToCa15-3
Other,complaint
Other,complementaryApproaches
Other,completionOfReproductivePlans
Mood,complex
Other,complexConsulting
Mood,complexDueToPotentialFoetalRisksInSettingOfMaternalTreatment
Mood,complexSurgeries
Mood,complexTreatmentAlgorithms
Interference,complication
Components,components
Testing,comprehensiveResearchData
Testing,comprehensiveSearch
Computer,Computer
Other,concentrations
Testing,concentrationsOfVegf-aInComparisonToCa15-3InBreastCancer
Care,concernForExistenceOfCancerCellsInGrafts
Other,concerns
Women,conclusionsWomen
Other,conditions
Other,conducted
Other,confirmed
HER2-positive,confirmedUnilateralHer2-positiveBreastCancer
Conflict,conflict
Restoration,conflictBetweenCareOfMother
Conjugate,conjugatedEquineEstrogen
Other,connected
Consensus,consensus
Consensus-based,consensus-based
Danger,consensusOnAssociationBetweenExposureToDdt
Other,consequencesForSurvival/relapse
Other,consequentlyHaveDeveloped
Other,conservativeTreatment
Considerable,considerableNumber
Other,considered
Other,consistent
Accumulation,consistentMass-spectralData
Other,consultations
Other,context
Other,contextOfBreastCancer
Other,contexts
Purpose,contraceptionUse
Purpose,contraceptiveUse
Conflict,contrast
Conflict,contrastAfterInjection
Conflict,contrastAgents
Contribution,contribution
Mood,control
Mood,controlGroup
Other,controls
Mood,controlTrial
Other,controversial
MABA,conventionalBafifty-fivePatientsUndergoingViaMabaForPtmc
Other,conventionalTreatmentProcesses
Other,conventionalX-rayMammography
Other,convolutionalNeuralNetworks
Platform,copyright
Output,correctionMethod
Other,correlated
Correlation,correlation
Coefficient,correlationCoefficient
Coefficient,correlationCoefficientOnMetabricTrainingSet
Odds,correlationsBetweenOdds
Number,correspondingCohort
Image,correspondingHistologyImage
Costs,costs
Other,couldConsidered
Other,couldDetected
Other,couldDetectedByMammographyBySelf-detection
Other,couldDetectedEarly
16,couldIndependentPrognosticBiomarkerForMPatients'Outcomes
Other,couldPotentialBiomarker
Entry,counseling
Township,country
Water,course
Contribution,coverage
Contribution,coverageRates
Cox,coxHazardRegressionAnalysis
Cox,coxHazardRegressionModels
Cox,coxModel
Cox,coxProportionalHazardModel
Cox,coxProportionalHazardRegressionModels
Other,cpgIslands
Craniotomy,craniotomy
Other,created
Other,critical
Purpose,criticalRole
Scientific,criticalScientificBase
Scientific,criticalScientificBaseForPrecisionMedicineInBreastCancer
Other,cross-sectionalCategories
Focus,cross-sectionalStudy
Cross-validation,cross-validation
Other,crucial
Restoration,crucialImpactOnDevelopmentOfBreastCancer
Purpose,crucialRole
Other,cruciferousVegetables
Other,Cryopreservation
Other,cscMarkers
Number,cssBenefit
CTC,CTC
CTC,ctcCounts
Nonparticipation,ctcIsolationTechniques
Other,CTCs
Cohort,ctcsFromPeripheralBlood
Other,CTIBL
CTn,cTn
Levels,ctnLevels
Actual,currentAnalysis
Actual,currentCancerResearch
Actual,currentFollow-up
Other,currentlyInsufficient
Actual,currentMeans
Actual,currentResults
Actual,currentUsersOfLongerDuration
Utilized,currentUtilizedHistopathologicBiomarkers
Other,cutaneousManifestationsOfBreastCancer
Cutoff,cutoff
Values,cutoffValues
Other,CXCR4
Other,cylindricalGeometries
Comparisons,cytohistologicalComparisons
Testing,cytologicalExamination
Cytology,cytology
Disease,cytotoxicity
DOX,cytotoxicityOfFreeDoxMolecules
Other,D538G
Mood,danger
Accumulation,data
Other,Data
Analytics,dataAnalytics
Alpha,dataOfN=
Distance,date
Other,DAU
Disease,DCIS
Other,dcisDiagnosis
Other,dcisWithMicroinvasion
Other,DCR
Chemical,DDE
Chemical,DDT
Danger,ddtExposure
DDTs,DDTs
Sprays,ddtSprays
Conflict,dealingWithEndocrineResistanceInPatientsWithBreastCancer
Disease,death
Conflict,deathInWomenWorldwide
Debated,debated
Other,decades
Number,decrease
Reduced,decreased
BPE,decreasedBpe
Ecchymosis,decreasedExpression
Reduced,decreasedGrowth
Reduced,decreasedRisk
Reduced,decreasedRiskOfBreastCancerInFemaleAdPatients
Other,decreases
Other,decreasesInMortalityRates
Other,deep-CNN
Learning,deepLearning
Other,defectStudies
Distinct,defined
Distinct,definedSubtype
Other,delay
Other,Delays
Other,delaysinTreatment
Interference,delivery
Demographics,Demographics
Other,demonstrate
Binding,denosumabInjection
Other,denseBreasts
Other,dependent
Pathologic,dependentOnRigorousPathologicEvaluationOnAdministrationOfTreatmentDictatedByTumorBiology
Depletion,depletion
Other,Depletion
MiRNAs,deregulatedMirnas
Other,described
Type,description
Other,descriptive
Caregiver,descriptive-analyticCross-sectionalType160FemalePatientsWasselected
Focus,descriptiveStudy
Other,designed
Gene,DESI-MSI
Desirable,desirable
Finding,despiteTheirRarityShouldConsidered
Other,detailedRoles
Other,detected
16,detectedByImmunohistochemistryInApproximately70PercecntOfInvasiveBreastCancers
Testing,detectedThroughScreeningThroughSigns
Discovery,detection
Discovery,detectionMethod
Other,detectionofBreastCancer
Discovery,detectionOfBreastCancerInWomen
Discovery,detectionOfCancer
Discovery,detectionOfMicrocalcificationInMammograms
Discovery,detectionRate
Discovery,detectionRateOfMutationsHigherThanThatDescribedInLiterature
Discovery,determinationOfUnderlyingBiologyWithinTumors
Other,determine
Other,determined
Other,determining
Other,developed
Restoration,Development
Restoration,developmentOfBrainCancers
Restoration,developmentOfBreastCancer
Restoration,developmentOfEffectiveDrugsForTreatmentOfHormone-dependentBreastCancer
Restoration,developmentOfGraphicallyTailoredScreeningTool
Restoration,developmentOfLymphedema
Restoration,developmentOfNewDrugs
Restoration,developmentOfPolicies
Restoration,developmentOfSubsequentLung/bronchusCancer
Other,diagnosed
Other,diagnoses
Other,diagnosis
Positivity,diagnosisAccuracy
Syndromes,diagnosisOfAcuteCoronarySyndromes
Other,diagnosisOfBreastCancer
Other,diagnosisOfCancer
Other,diagnosisOfEstrogenReceptor
Other,diagnosisOfGallbladderMetastasis
Other,diagnosisOfPatientsWithBreastCancer
Signature,diagnosisOfResponseToTreatment
Other,diagnosisOfSulinicalPrimaryCarcinomas
Positivity,diagnosticAccuracy
Other,diagnosticEvaluation
Purpose,diagnosticRole
Other,diagnosticUncertainty
Learning,dictionaryLearning
Other,diet
Conflict,difference
Conflict,differenceBetweenClearcellPlatformsForIsolatingCtcs
Distinct,differenceBetweenDifferentBreastCancerSubtypes
Distinct,different
Distinct,differentBreastCancerMolecularSubtypes
Distinct,differentContrastAgent
Distinct,differentDetectionRates
Distinct,differentDetectionRatesInBreastCancerPatients
Distinct,differentFunctionRegions
Distinct,differentGeneticProfile
Distinct,differentHistologicalAspects
Other,differentialDiagnoses
Other,differentialDiagnosis
Other,differentialDiagnosisInPatientsWithHistoryOfBreastSurgery
Other,differentiallyExpressedInBreastCancerCells
Differentials,differentials
Other,differentiation
Subtypes,differentiationBetweenBreastCancerInVariousSubtypesOfBreastCancer
Distinct,differentLong-termSurvival
Other,differentmethodsOfSelf-treatment
Distinct,differentPatientRaces
Distinct,differentPhenotypes
Distinct,differentPhotosensitizerForPhotodynamicTherapy
Distinct,differentPrognosis
Distinct,differentProtocols
Distinct,differentStages
Distinct,differentStudies
Distinct,differentSubtype
Chemical,diindolylmethane
Reduced,diminishedOncospheroid-formingCapacityOfBreastCancerCells
Post,directEffects
Benchmark,directTargetGene
Other,disadvantages
Interference,discovery
Purpose,discrete-timePartiallyObservableMarkovDecisionProcess
Other,discussed
Other,Disease
Distinct,diseaseDefinedByTumor
Other,diseases
Interference,disposition
Other,dissection
Other,dissectionOfLymphNodes
Other,disseminatedDisease
Distinct,distinct
Hereditary,distinctiveGeneticModifications
Other,distributions
Other,diverse
Other,diverseBiologicalProcesses
Other,divided
DNA,dnaMethylation
DNA,dnaMethylationDifferencesBetweenTumorBreastTissue
Other,documented
Danger,documentedAsImportantTumor-promotingAgentForSeveralHumanCarcinomasIncludingBreastCancer
Allele,dominantArms
Other,doses
Other,double-maintenanceTherapy
Other,doublingTimeOfOccult
Other,downregulated
Other,down-regulated
Other,down-regulatedInTissues
CS/Bio-MOF,doxUptakeByCs/bio-mof
Other,DPV
Intensity,dramaticallyIncreasedAmount
Other,drastic
Other,drawbacks
Other,driven
Binding,drugBinding
Interference,drugDeliveryStrategies
Mood,dryness
DSCAM-AS1,DSCAM-AS1
Ecchymosis,dscam-as1Expression
Reporter,dual-luciferaseReporterAssays
Conflict,dual-phaseContrast
Disease,ductalCarcinoma
Other,ductalCarcinoma
Evolve,duringAgeAssociatedWithIncreaseOf8MoreFemaleBreastCancerCasesPer100000DuringAge50-54
Conflict,dynamicContrast
Disease,dyspareunia
Other,dysregulation
Hazard,earlyBiomarkersOfBreastCancerRisk
Other,earlyBreastCancer
Discovery,earlyBreastCancerDetectionSystems
Other,earlyBreastCancerSurgery
Other,earlyCancerDiagnosis
Other,earlyDiagnosis
Other,earlyStage
Other,earlyStageDiagnosisOfTumors
Ecchymosis,ecchymosis
Alpha,eConcentration
Type,edition
Symptom,effect
Actual,effective
Actual,effectiveDiagnosisOfBreastCancer
Other,effectiveness
Distinct,effectivenessOfDifferentNpatsOnQolInPatientsWithBreastCancer
Testing,effectivenessOfNationalScreeningProgrammes
Symptom,effectOfBaicalinInBreastCancer
Symptom,effectOfDdtSpraysOnBreastCancerIncidenceRate
Symptom,effectOfDscam-as1
Other,effects
PCOS,effectsOfPcosOnRisksOfGynecologicCancer
Other,effectsOfTreatment
Signatures,efficientSignaturesForClinicalDiagnosis
Type,eighthEdition
Cohort,elderlyPatients
Other,electiveCholecystectomyForSymptomaticCholelithiasis
Other,electricalDouble-layerCapacitors
Disease,elevatedLesion
Immunohistochemistry,ELISA
Elusive,elusive
Targeted,elusiveToTargetedTherapies-theTriple-negativeBreastCancer
Food,embeddingIntoReproducingKernelHilbertSpace
Intensity,emergingPublicHealthProblemInLowCountries
Other,emergingTechnology
Other,EMH
Intensity,emphasis
Clinical-pathological,empiricalTreatmentsBasedOnClinical-pathologicalCharacteristicsToUseOfTargetedApproaches
Other,employed
Nonparticipation,endocrineResistance
Nonparticipation,endocrineTherapyResistance
Image,energyImage
Ecchymosis,enforcedExpression
Other,englishLiterature
Other,enhancedPossibility
Image,enhancementOfImage
Enhancer,enhancerRegions
Other,enrolled
Other,epidemiologicalFeatures
Other,epigeneticAberrations
Exposure,equivalentPerformance
Signalling,eralphaSignalling
ERalpha,eralphaTranscription
Gene,ERBB2
Other,erCscs
Entry,er-dependentTranscriptionalActivationViaTransactivationFunction1
Other,erEvaluation
Immunohistochemistry,erImmunohistochemistry
ER-positive/human,er-positive/humanEpidermalGrowthFactorReceptorType2-negativeBreastCancers
Other,er-positiveBreastCancer
Gene,ESR1
Mutations,esr1-activatingMutations
Alterations,esr1Alterations
Mutations,esr1Mutations
Somatic,esr1SomaticAlterations
Water,essential
Water,essentialRole
Other,established
Other,estimated
Estimates,estimates
Chemical,estrogen
Estrogen-alone,estrogen-aloneArmOfWhi
Danger,estrogenicExposure
Other,estrogenReceptor
Estrogen,estrogenReceptor-alpha
Other,estrogen-receptorAmongOtherMarkers
Chemical,estrogens
Other,ET
European,europeanCountries
Other,evaluated
Vivo,evaluatedInVivo
Other,evaluation
Interference,evenLessFrequentComplication
Personalized,evenMorePersonalizedFollow-upSchedules
Radiotherapy,evenSeveralChemotherapySessions
MiRNA-21,eventHybridizationOfMirna-21Biomarker
Other,events
Other,eventualKnowledge
Symptom,evidence
Other,evidence-basedRecommendations
Conflict,evidencedByIncreaseInContrastAfterInjection
Symptom,evidenceForbenefits
Evolve,evolve
Evolve,evolveTowardLessSurgery
Testing,examination
Other,examined
Exposure,excellentPerformance
Water,excellentPerformanceInFieldOfMedicalImagesDiagnosis
Mood,excellentRegionalControl
Craniotomy,excision
Other,excision/lumpectomy
Other,exercise
Other,existence
Subjective,existingEvidenceOnPersonalGoal-settingAmongWomenWithBreastCancerDiagnosis
Benchmark,exon32OfMammalianTargetOfRapamycin
Other,expected
Correlation,expectedInverseCorrelation
DDTs,expectedInverseCorrelationOfSerumDdtsWithBmi
Food,experience
Other,experiences
Focus,experimentalStudyOfCryo-stabilityOfCancerCells
Other,experts
Other,explored
Danger,exposure
Other,expressed
Other,expressedSeparately
Ecchymosis,expression
Ecchymosis,expressionInBreastCancer
Ecchymosis,expressionLevel
Levels,expressionLevels
Circulating,expressionOf6CirculatingMirnasInOperablePatients
Ecchymosis,expressionOfCxcChemokineReceptor-4
Ecchymosis,expressionOfMir-511InBreastCancer
Ecchymosis,expressionOfRrm2
Ecchymosis,expressionProfileOfNek6In133BreastCancerSpecimens
Care,extensiveAttentionOfResearchers
Other,extensiveExploration
Other,extensiveMolecular
Ecchymosis,extramedullaryHaematopoiesis
Learning,extremeLearningMachineClassification
Other,fabricated
Purpose,facilitatingRole
Provider,factor
Other,factor-1Scores
Factor,factorAnalysis
Factors,factors
Other,Factors
Factors,factorsRelatedToPresenceOfMetastaticDiseaseAtDiagnosis
Other,Familiarity
Spouse,familyHistoryOfDisease
Spouse,familyImpact
Spouse,familySupport
Disease,fanconiAnemia
Network,faSignalingNetwork
Sleep,fastDayBefore
Cohort,fastingBlood
Percent,fastRate
16,f-boxProtein22
Other,Fbxo22
Description,fbxo22-dependentManner
Contribution,fearOfPartnerLoss
Other,feasible
Nonparticipation,feasibleCtcIsolationTechniques
Quantification,feasibleInProperlySelectedCasesWithAsymptomaticNeuromasAfterAccurateTissueSampling
Other,features
Other,featuresFromImages
Adult,february2012InNargisDuttMemorialCancerHospital
Young,female
Young,femalePatient
Young,femalePatients
Young,femalePatientsWithAd
Spouse,femaleSibling
Spread,fewerInstancesOfSpreadToLungs
Chosen,fewPercentOfWomen
Chosen,fewStudies
FFDM,FFDM
Disease,fibroadenoma
Fibroblasts,fibroblasts
Fibroblasts,fibroblastsAdjacent
Water,field
Water,fieldOfBreastCancerDetection
Water,fieldOfMedicalImagesDiagnosis
Other,figures
Other,filipinoWomen
Description,finalMultipleRegressionModel
Discovery,finding
Other,findings
Aspiration,fine-needleAspirationCytology
Focus,firmlyPlaceWithRecentTrendsTowardDecreasedRatesOfRe-excision
Distance,firstDataOnPre-diagnosisConcentrationsOfSrankl
Distance,firstDiagnosis
Distance,firstFiveFacebookOpenBreastCancerGroupsInYear2016
Other,first-lineTreatment
Global,firstOrganisedRound
Pathologically,firstPatientsWithPathologicallyTumor-freeNodes
Distance,firstSteps
Symptom,firstSymptom
Distance,firstTime
Distance,firstTimeIn1984
Testing,fisherAnalysis
Testing,fisherDiscriminantAnalysis
Other,fitted
Other,five
Other,fiveGroups
Other,fiveYearRfsrate
Other,flankingCgi
Fertility,flowCytometry
Fertility,flowRate
Other,fluorescenceImaging
Alpha,fluorescenceImagingExVivo
Focus,focus
Other,followed
Conflict,followedFromDateOfFirstDiagnosisOfAdToEndOf2013
Other,following
Other,Follow-up
Testing,follow-up
Testing,follow-upSchemes
Food,foodRecommendations
Forefront,forefront
Testing,forefrontOfResearch
Formed,formed
Formed,formedByCo-encapsulationOfNear-infraredFluorophoreInPegylatedMicelles
Design,formulation
Actual,formulationOfEffectiveManagementPlanForAt-riskWomen
Race/color,forRace/colorVariableEstimatedWithAdjustmentForStatus
93,forThoseWithNormalLvef93Percecnt
Other,forWomenWithBreastCancerMayMoreFeasible
Other,found
HER2,foundBetweenMolecularSubtypesWithHer2
Number,foundInPcosCohortThanInComparisonCohort
Other,fourTypesOfBreastCancer
FOXC1,FOXC1
Other,foxc1-knockdownBt549Cells
Other,framework
Predominant,frequentCancer
Considerable,frequentLargeSingleGiantCellsWithNucleiLocatedPredominantlyWithinSupsularSinuses
Predominant,frequentMutations
Other,FT
Purpose,function
Other,functionalAssessments
Other,functions
Restoration,furtherDevelopment
Other,furthermoreAssociated
Other,furthermoreMoreLikely
Other,furthermoreSignificantlyMoreLikely
Testing,furtherResearch
Other,furtherStudies
Other,furtherTissue
Will,furtherUnderstanding
Other,fused
Other,fusionProteinsWithHaloTag
Other,future
Other,futureClinicalStudies
Other,futureInterventions
Gene,FXYD3
Amplification,fxyd3Amplification
16,G
Fertility,g1/s-phaseCellCycleArrest
Gene,geneExpressionLevel
Ecchymosis,geneExpressionUpregulationInBreastCancer
Subgroup,generalBreastCancerPopulation
Susceptibility,generalHealth
Other,generallyReserved
Subgroup,generalPopulation
Obstetrician,generalRadiologistAboutSystemicDiseases
Genes,genes
Genes,genesInvolved
Hereditary,geneticChanges
Hybrid,geneticMutation
Other,geometries
Basis,given
Global,globalHealth
Ecchymosis,glut1Expression
Glycosylation,glycosylation
Caregiver,glycosylationOfMembraneTypeMr
Food,goal
Goal-setting,goal-setting
Other,gonadotropin
Restoration,good
Restoration,goodCorrelationBetweenErAnalysedWithCytAtDiagnosisAnalysedWithIhcInArchivedFfpeTissueFromSameTumour
Restoration,goodDiagnosticAbility
Restoration,goodDiagnosticPerformance
Restoration,goodQualityEvidence
Restoration,goodTolerabilitytheApatinib
Other,grade
Other,grafts
Collision,greatClinicalImpactForTumorDiagnosis
Greater,greater
Mood,greaterthanorequalto10PercecntDecline
16,greaterthanorequalto10PercecntReductionInLvef
Oxidation,greaterthanorequaltoReduction
Other,greatPotentialInDiagnosisTherapyOfCancers
Resistance,greatPotentialOfClinicalApplication
Other,greatProgress
Description,greatPromise
Subset,group
Subset,group1
Subset,group2
Other,groups
Finding,growth
Finding,growthOfFbxo22-depletedEr-positiveBreastCancers
GTPase,GTPase
GTPase,gtpaseInBreastCancerCells
Other,guidedImagery
Guidelines,guidelines
Other,gynaecologicalMetastases
Other,HADS
Other,haMoietyForPdt
Filter,handheldProbeCapable
Advantage,handicap
Other,harmfulorHarmlessTissues
Decrease,harmToHealthAmongRuralWomenWithIncrementalCost-effectivenessRatio
Distinct,hasAlreadyAssociatedWithDifferentCancersNon-hodgkin'sLymphoma
Other,hasApplied
Other,hasAssociated
Focused,hasFocused
Focused,hasFocusedOnTumourCellsPrimarily
Other,hasFound
Other,hasInconsistent
Other,hasMade
Other,hasMadeInMolecularSubtypingOfBreastCancer
Other,hasProposed
Other,hasPut
Immunohistochemistry,hasPutOnIntrinsicSubtypingBasedInPresenceOfClassicalImmunohistochemistry
Other,hasRecentlyProposedAsCrucialRegulatorOfTriple-negativeBreastCancer
Other,hasReported
Other,hasSuggested
Utilized,hasUsed
Utilized,hasWidelyUsed
Other,haveAssociated
Mood,haveAssociatedWithNippleAreolaComplexInvolvementInPatientsWithBreastCancer
Other,haveBackbone
Platinum,haveBackboneOfSuchEnormousStridesOfAu
Other,haveCenterstage
Other,haveClarified
Other,haveDescribed
Signature,haveDescribedInResponseToNeoadjuvantChemotherapyParticularlyInAssociationWithHerceptinTreatment
Other,haveDeveloped
Other,haveDiscovered
Other,haveObserved
Other,haveProducedInLaboratories
Other,haveReported
Focus,haveReportedForFirstTimeInCaninesInStudy
Other,haveReportedInOnly003-06PercecntOfBreastCancers
Other,haveReportedMainlyAfterMastectomy
Interference,haveStudiedInTermsOfCrosstalkBetweenEstrogenReceptorAlpha
Utilized,haveUsed
Intensity,haveValidatedByClinicalStudiesInCardiotoxicityDiagnosisInPatientsTreatedWithHighDosesOfAnthracyclinesAloneInCombinationMainlyWithTrastuzumab
Hazard,hazardRates
Hazard,hazardRatiosWith95PercecntConfidenceIntervals
Susceptibility,health
Susceptibility,healthBehaviours
Care,healthcareCost
Restoration,healthCareSector
Care,healthcareUtilization
Susceptibility,healthCenters
Susceptibility,healthExpectancyOfItspopulation
Other,healthInitiative
Disease,heartFailure
Symptom,heavySymptomBurden
Other,henceMainlyBased
Testing,henceMajorResearchGoal
Gene,HER2
Other,her2/hrTripleNegativeTnmStages
Overexpressing,her2Overexpressing
Alpha,her2-positiveA
Disease,her2-positiveBreastCancer
Other,her2-positiveInvasiveDuctalCarcinoma
HER2,her2Status
Herceptin,Herceptin
Hereditary,hereditaryCausesOfChorea
Disease,hereditaryDisease
Heterogeneity,heterogeneity
Other,heterogeneous
Global,heterogeneousCancerInFemalePatientsWorldwide
Disease,heterogeneousDisease
Entry,heterogeneousDiseaseInItsHistologicAppearance
Other,heterogeneousPopulationsOfCellsWithHierarchicalOrganizationDrivenByCancerStemCells
Intensity,high
Intensity,highAmountOfDox
Intensity,highCorrelation
Contribution,highCoverage
Focus,highDetectionRateOfSentinelLymphNodeComparableWithRiMethod
Other,higher
Intensity,higherProportion
Intensity,higherProportionOfPatientsWithLymphedema
Other,higher-qualityImaging
Other,higherRatesOfMisdiagnosisForBreastCancer
Description,higherResolution
Other,higherRisks
Delays,higherRisksOfTreatmentDelays
Other,highestIncidenceAmongMalignanciesDiagnosedInWomen
Exposure,highestPerformance
Hazard,highestRisk
SE,highestSe
Subset,highestSeInTotalGroup
Intensity,highExpression
Ecchymosis,highGlut1Expression
Intensity,highIndex
Hazard,highlyDiverseGroupOfMalignantNeoplasiaWithPoorOutcome
Actual,highlyEffective
Other,highlyExpressed
Genes,highlyPenetrantGenes
Sensitive,highlySensitiveNano-biosensor
Intensity,highMortalityRateForFemales
Other,high-resolutionImages
Intensity,highSensitivity
Intensity,highVolumeAcademicCenters
Testing,histologicalExamination
Other,histologicGradeInBreastCancer
Cytology,histology
Other,histoneModifications
Testing,histopathologicalExamination
Other,histopathologicallyProvedBreastTumors
Other,histopathologicalreports
Other,history
Other,historyOfBreastCancer
Other,historyOfBreast-conservingSurgery
Somatic,historyPhysicalExamFindings
Purpose,hormonalContraceptionUse
Other,hormone-dependentPositiveBreastCancer
Other,hormoneReceptor-positiveTumors
Number,hospitalCohort
Other,hospitalFromJanuary2016ToFebruary2017
Elusive,howeverElusive
Greaterfor,howeverGreaterforPatientsTreatedInAlmatyCity
Other,howeverHaveClarified
Other,howeverKnown
Other,howeverMoreDrastic
Other,howeverMuchLower
Other,howeverNon-ideal
Switched,howeverSwitched
Other,howeverUnderutilized
Other,howeverWidelyUnderstood
Gene,HR
Disease,HT
Other,hugeVolumes
Species,human
Other,humanBiofluid
Entry,humanBody
Other,humanChorionicGonadotropin
Provider,humanEpidermalGrowthFactorReceptor2ReceptorStatus
Other,humanErrors
Other,humanLife
Other,hundreds
Hybrid,hybridCultures
Symptom,hyperglycemia
Hypomethylated,hypomethylated
Hypomethylation,hypomethylation
Sites,hypomethylationSites
Other,hypothesis
Other,ICER
Other,icgFluorescenceMethod
Other,identifiablePcrResults
Finding,identification
Other,Identification
Distinct,identificationOfDistinctiveGeneticModificationsInDifferentBreastCancerMolecularSubtypes
Finding,identificationOfPredictiveBiomarkersForSelectionOfOptimalTreatment
Other,identified
Other,illiterate
Image,image
Intensity,imageQuality
Other,imagery
Other,images
Image,imageSegmentation
Other,imaging
Other,imagingIndexes
Other,imagingInvestigations
Other,imagingModalities
Technique,imagingTechnique
Necessity,immediateUnmetNeed
Necessity,immediateUnmetNeedInClinicalPractice
Other,immune-mediatedCancer-associatedDisorders
Restoration,immunocaptureOfMarker
Immunohistochemical,immunohistochemicalAnalysis
Discovery,immunohistochemicalDetectionOfErPerformedInRoutineClinicalPractice
Other,immunohistochemicalTests
Other,Immunohistochemistry
Collision,impact
Benchmark,impairedBaselineCardiacFunctionExperience
Apoptosis,impededApoptosis
Other,imperative
Other,importance
Testing,importanceOfNondestructiveTestingInDefectStudies
Fertility,importanceOfProactivelyAddressingFertility
Other,important
Resistance,importantApplicationProspects
Other,importantComponent
Other,importantContributors
Advantage,importantCopingResource
Other,importantForDiagnosis
Other,importantInsightsIntoDiagnosisOfPatientsWithDisease
Subgroup,importantlyCouldPotentialDiagnosticBiomarkerInEthnicPopulation
Other,importantPotential
Other,importantProblem
Purpose,importantRole
Other,importantTumor-promotingCells
Other,improved
Other,improvedCancerTreatment
Discovery,improvedDetection
Other,improvedDiagnosis
Intensity,improvedQualityOfLife
Will,improvedUnderstanding
Susceptibility,improvement
Susceptibility,improvementInClassificationOfMalignantLesions
Amplification,inAdditionFurtherConfirmedInEarlyStage
Food,inAssay
Predominant,inBelgiumMostFrequentWomen'sCancerAccountingForTo353PercecntOfCases
Other,inBreastTumorsKnownAsBreastCscs
Systematic,inCanadaOfferedInOrganizedPrograms
Contribution,inCaseReportTypicalOfAdvance
Interference,inCaseSecondaryToProximalBronchialObstruction
CNN,inception-v3Cnn
Other,incidence
Other,incidenceAmongMalignancies
Factors,incidenceFactors
Lung/bronchus,incidenceFactorsOfSubsequentLung/bronchusPrimaries
Other,incidenceRates
Discovery,incidentalFinding
Other,inclined
Other,included
Other,included.When
Focus,includedInStudy
Other,including
Amplification,inclusion
Craniotomy,incompleteExcisionOfMalignantTissues
Basis,inConclusionDownregulatedInBreastCancer
Evolve,inConclusionMajorHereditaryBreastCancerGenesIrrespectiveOfAgeAtDiagnosisInJapaneseWomen
Number,inConclusionPathogenicFeatureInPrimarySamples
Necessity,inConclusionStillNecessaryForAdoptionOfCtnAsRoutineClinicalBiomarkerInPatientsWithBreastCancer
Nonparticipation,inConclusionStronglyAssociatedWithNonparticipationInS
Other,inconsistentResults
Decrease,increase
Other,Increase
Other,increased
Other,increasedMalignantPotential
Hazard,increasedRisk
Hazard,increasedRiskOfEndometrialCancer
Hazard,increasedRiskOfMortality/relapse
Therapy-related,increasedRiskOfTherapy-relatedMorbidity
Purpose,increasedRiskWithUseOfLevonorgestrelIntrauterineSystem-bothOfPotentiallyImportantFindings
Ecchymosis,increasedRonExpression
Other,increases
Number,increaseWithNumberOfSprays
Number,increasingNumber
Other,independent
Other,independentlyAssociated
Provider,independentPrognosticFactor
Provider,independentPrognosticFactorForDfsOfEarlyStageBreastCancer
Other,independentPrognosticPredictor
Other,indicative
Output,indicator
Output,indicatorOfNacEffectiveness
Other,indispensable
Hybrid,individualRiskOfRecurrence
Individuals,Individuals
Other,individuals
Entry,induction
Other,inexpensive
Technique,inexpensiveTechnique
Other,infiltrationSimilar
Other,infiltrativeLesion
Other,inflammatoryDiseases
Disease,inflammatoryTumour
Intensity,influenceOfSleepQualityOnPmInPatientsTreatedWithHt
Other,influences
Other,inFluorescenceImaging
Entry,information
Other,Information
Infrared,infraredFluorescentDye
Infrared,infraredFluorescentImagingInTripleNegativeInVitro
Hereditary,inheritableBi-objectiveCombinatorialGeneticAlgorithm
Other,inhibited
Ecchymosis,inhibition
Other,inHumanBreastCancerHasReported
Alpha,initialPresentationOfInvasiveBreastCancer
Alpha,initialTreatmentAfterWhich
Entry,initiationOfBreastMalignancy
Entry,initiationOfPromptTherapy
Collision,injury
Long-term,inLongTermHasFound
Contribution,inMarch2014BroadcastedAsPart
Other,inMultivariateModelsRelatedToPerformanceStatus
Other,inNearFutureContribute
Utilized,inPaperUsed
Focus,inPresentStudyConductedBetweenMcf-7Tamoxifen-resistantLcc2CellLines
Focus,inPresentStudyPerformedFor9Features
Other,inPrimaryBreastCancerTumorsExpressedDuringNeoplasticTransformation
Other,insight
Other,insights
Focus,inStudyDevelopedByCell-selex
Focus,inStudyDevelopedForHighlyEfficientIsolationOfCtcsFromBreastCancerPatients
Restoration,inStudyFusedWithMouseMyelomaCellLineSp2/0InPresence
Other,insufficient
Techniques,intelligentTechniques
Other,intensive
Advantage,interest
Interference,interference
Distance,interimStageInProgressionFromDcisToInvasiveBreastCancer
Guidelines,internationalGuidelines
Other,interplay
Other,interpretation
Signature,interval
Signature,intervalBetweenDiagnosis
Interference,intervention
Interference,interventionArm
Other,interview
Other,intopreGroups
Evolve,inTotalDiagnosedUnderAgeOf50
Decrease,inTotalMatchedToCasesOnBirthYear
Other,intracellularLevel
Yoga,intralaboratoryValidationSet
Cytology,intraoperativeScrapeCytology
Heterogeneity,intratumoralHeterogeneityOfKindOfTumor
Filter,intravenousAdministrationOfOsteopontin-750Probe
Parameters,intravoxelIncoherentMotionParameters
Spread,invasion
Disease,invasiveBreastCancer
Disease,invasiveBreastCarcinoma
Other,invasiveCarcinomaBreast
Testing,invasiveDiseaseretrospectiveAnalysisOf219Cases
Disease,invasiveDuctalCarcinoma
Cytology,invasiveLobularHistology
Other,inverselyCorrelated
Other,investigated
Other,investigatedOnly
Investigation,Investigation
Other,involved
Nonparticipation,involvement
Interference,inWorkSynthesizedAsSystemForDeliveryOfDoxorubicinInTreatmentOfBreastCancer
Other,iraqiWomenWhencomparedToWesternWorld
Hyperintense,irregularHyperintenseLesion
T2,irregularHyperintenseLesionInT2InLeftParietalRegion
Other,Isolation
Other,Israel
Replaced,isReplaced
Situations,isReplacedWithRadiotherapyInSituations
2-Jan,isSentinelLymphNodesMetastasesTo1-2Nodes
Issues,issues
Conflict,issuesOfExistingContrastAgents
Issues,issuesRelatedToTherapeuticSequencingInLocalTherapyOfBreastCancer
Other,It
Numerous,itInvolvesInManyCrucialMetabolicProcesses
Other,its
Exposure,itsDiagnosticPerformance
Ecchymosis,itsExpression
Its,itsExpressionLevel
Entry,itsHistologicAppearance
Platinum,itsMinimalSilverIonReleaseProfiles
Exposure,itsPerformance
Cohort,itsPoorPrognosis
Purpose,itsRole
Other,iU22
Parameters,ivimParameters
JAK-STAT,jak-statPathway
Other,Japan
Japanese,Japanese
Other,kaplanMeierCurves
Other,kaplan-meierCurves
Isolation,kaplan-meierRegressionMethods
Kazakhstan,Kazakhstan
KDM4B,KDM4B
Kenya,Kenya
Food,kernelApproach
Binding,key
Sites,keyHypomethylationSites
Other,keys
Craniotomy,keysToSuccessfulChestWallResectionForLocallyRecurrentBreastCancerAfterMastectomy
Other,Ki67
Other,kind
Other,kinds
Other,knockdown
Other,knowledge
16,knowledgeOfM
Summaries,knowledgeSummaries
Other,known
Other,knownHeterogeneousDisease
Discovery,label-freeDetection
Considerable,large
Considerable,largeBreastCancerTissueMicroarray
Considerable,largeCells
Other,largelyConsistent
Other,large-scaleStudies
Testing,lastFollow-upTime
Late-stage,late-stage
Late-stage,late-stageCancerDiagnosis
Conflict,leadingCauseOfDeathAmongGynecologicNeoplasias
Learning,learning
Other,leastAbsoluteShrinkage
Parietal,leftParietalRegion
Other,lesion
Other,lessLikely
Other,lessVisits
Other,leucocytes
Other,level
Levels,levels
Levels,levelsOfEralphaProtein
Other,life
Signature,lifestyleModification
Other,life-threatening
Subset,ligand-bindingDomainAllInBreastCancerSamplesFromPatientsPreviouslyTreatedWithEndocrineTherapy
Other,likelihood
Discovery,likelihoodOfDetectionOfMicrometastases
Other,likely
Paraneoplastic,likelyParaneoplastic
Limitations,limitations
Other,limitedLiterature
Exposure,limitedPerformanceForWomenWithDenseBreasts
Linear,linearRegression
Testing,linerRegressionAnalysis
Other,linked
Other,lipidProfiles
Output,lisbonRegion
Other,literature
Other,little
Survival,littleSurvivalVariance
Other,lobularCarcinoma
Other,localExcision/lumpectomy
Type,localizedDescription
Type,localizedDescriptionOfBreastCancer
Other,locallyAdvancedBreastCancer
Other,localRecurrence
Other,localTherapy
Other,localTherapyOfBreastCancer
Finding,locoregionalDiseaseOfUnspecifiedLocation
Locoregional,locoregionalRadiotherapy
Other,logisticregressions
Periods,longerPeriods
PFS,longerPfs
Noncoding,longNoncodingRnas
Estimates,long-termEstimates
Purpose,long-termUse
Contribution,loss
Contribution,lossOf020Quality-adjustedLifeYears
Intensity,lowClassificationAccuracies
Intensity,lowCountries
Intensity,lowCtnLevels
Intensity,lowDiagnosticSensitivityForWomenWithDenseBreasts
Other,lower
Hazard,lowerCumulativeHazardRates
Accumulation,lowerInEasternThanNorthern/centralEurope
Intensity,lowLevel
Intensity,lowRiskLesions
Reporter,luciferaseReporterAssay
Other,luminalB-likePatients
Lung/bronchus,lung/bronchusMalignancies
Disease,lungCancer
Other,lungCancerInHuman
Other,lungChanges
Other,lungMetastasesFromBreastCancerPresented
Disease,LVEF
Other,LVI
Spread,lymphaticInvasion
Lymphedema,lymphedemaPatients
Other,lymphedemaseventyPatients
Focus,lymphNodeMetastasisInPatientsWithBreastCancer
Other,lymphocytes
16,M
Alpha,m
MAb,mab1e3
MABA,mabaSurgery
Macrophages,macrophages
Other,macrophage-targetedTreatmentStrategies
Other,made
Other,magneticResonanceImaging
Other,main
Description,mainChallenge
Contribution,mainContribution
Accumulation,mainlyEurope
Postmenopausal,mainlyPostmenopausalWomen
Other,mainMeasures
Purpose,mainObjective
Other,maintainedBreastCancerDatabase
Restoration,maintenanceOfErCancerStemCells
Other,major
Other,majorCscMarkersDescribedInInvasiveBreastCancer
Other,majority
Disease,maleBreastCancer
Young,malePatients
Other,malign
Disease,malignancies
Disease,malignancy
Other,malignant
Disease,malignantPleuralEffusion
Other,malignantProgressionOfBreastCancer
Focus,mammaryMetastasisFromCarcinomaOfOvarianOrigin
Other,mammograms
Mammographic,Mammographic
Testing,mammographicBreastCancerScreening
Other,mammographicImages
Other,Mammography
Other,Management
Other,managementOfTumour-relatedSymptoms
Other,manifold
Manufactured,manufactured
Other,manyBreastCancerPatients
Numerous,manyComputerVisionApplications
Other,manyFeatures
Numerous,manyPatients
Numerous,manyResearchers
Other,markedlyUp-regulated
Restoration,markerBands
Other,markers
Intensity,mass
Intensity,massInPosteriorFossaOfBrain
CircRNAs,massiveCircrnas
Intensity,massMedia
Intensity,massProduction
Intensity,massSpectrometry
Other,mastectomiedPatients
Mastectomies,mastectomies
Other,mastectomizedWomen
Other,mastectomy
Other,matched
Considerable,matchedHealthyTissues
Restoration,material
Detection,materialDetection
Matthews,matthewsCorrelationCoefficientOf8038Percecnt
Distinct,mayDistinctEntity
Restoration,mayGoodChoiceForUnilateralPtmc
Other,mayIndicativeOfBenignLesion
Necessity,mayNecessary
Utilized,mayUsed
Prior,mayUsedForTumourShrinkagePriorToSurgery
Other,MCC
Other,mda-mb-231Cells
Other,mean
Other,means
Other,meanTime
Subset,meanwhileBetterThanInCapecitabineGroup
Other,measurements
Other,measures
Mechanism,mechanism
Other,mechanisms
Evolve,medianAge
Evolve,medianDiagnosisAge
Adulthood,medianFollow-upOf48Years
Testing,medianFollow-upOf9·
Signature,medianInterval
Survival,medianProgression-freeSurvival
Other,medianTime
Testing,medicalDiagnosisOfBreastCancer
Testing,medicalHistory
Testing,medicalStatus
Other,medications
Restoration,megakaryocyteMarker
Other,megakaryocytes
Chemical,melatonin
Caregiver,membraneTypeMannoseReceptor
Caregiver,membraneTypeMr
Adult,memorialSloanKettering-integratedMutationProfilingOfActionableCancerTargets
Other,menopausalHormoneTherapy
Yoga,metabricTrainingSet
Other,metastasectomy
Disease,metastases
Disease,metastasis
Other,metastasisFromLobularBreastCarcinoma
Disease,metastaticBreastCancer
Disease,metastaticDisease
Other,metastaticDisease
Other,method
Other,methods
Purpose,methodsDesign
Other,methylation
Other,methylationStatus
PCDH10,methylationStatusOfPcdh10InBreastCancerTissues
Other,MethyLight
Testing,microarrayAnalysis
Microfluidic,microfluidicChips
Platform,microfluidicPlatform
Discovery,microfluidicsBiomarkerDetection
Disease,micrometastasis
Gene,microRNA-22
Levels,microrna-22ExpressionLevels
Other,microRNAs
Testing,microscopicExamination
Other,microscopicImages
Testing,microscopicTestingOfHematoxylin
Strategy,mightPromisingTherapeuticStrategyForHormone-therapyRefractoryEr
Other,minimal
Other,minimalRisksToNormalCells
Toxicity,minimumToxicityToNormalCells
Binding,mir-193b-3pBinding
Binding,mir-193b-3pBindingTo3UntranslatedRegionOfMorc4
MiR-193b-3p,mir-193b-3pIdentifiedAsRegulator
MiR-204-5p,miR-204-5p
MiR-34s,miR-34s
MiR-511,miR-511
Ecchymosis,mir-511Expression
MiR-511,mir-511Overexpression
MiRNA,mirnaExpressionProfiles
MiRNAs,miRNAs
Other,misdiagnosis
Other,missed
Other,mistaken
Other,mistakenDiagnosisOfMalignancy
Purpose,mixedMethodsDesign
Description,model
Other,modeled
Other,modified
Other,molecularAnalyses
Base,molecularBasis
Other,molecularChanges
Description,molecularDiagnosisMethodMake
Proliferation,molecularPathwaysInvolvedInPathogenesisOfProliferation
Regulatory,molecularRegulatoryNetworks
Monte,monteCarloFeatureFeatureMethod
Monte,monteCarloFeatureSelection-basedFeatureSelection-basedComputationalMethod
Mood,mood
Mood,moodOfLife
Gene,MORC4
MORC4,morc4Silencing
Spouse,morcFamilyCw-typeZincFinger4Overexpression
Other,moreAdvancedStages
Other,moreAdvancedStagingAtDiagnosisInWomen
Pure,moreAggressiveBiologicalNatureThanPureDcis
Alpha,moreComorbiditiesThanSPatients
Desirable,moreDesirable
Other,moreDirectional
Hypomethylated,moreEasilyHypomethylated
Actual,moreEffectiveTreatmentOfLungCancers
Other,moreInclined
Entry,moreInformationAboutFurtherStratificationOfBreastCancerSubtypes
Testing,moreIntensiveFollow-up
Other,moreLikely
Restoration,moreoverPerformedOnMcf-7CellLineInPresenceOfCs/bio-mofCarrier
Cohort,moreoverPoor
Other,moreoverRemarkablyIncreased
Other,moreoverStronglyRecommended
Other,moreRecentlyHaveDeveloped
Other,moreRecommended
Other,moreRefinedStratificationThanAnatomicStageAlone
Discovery,moreResearchLight
Satisfied,moreSatisfiedWithTheirCosmeticResultsThanThose
Targeted,moreTargetedAdjuvantTreatments
Differentials,morphologicalDifferentials
Parameters,morphologicParameters
Other,mortality
Percent,mortalityRate
Mortality,mortalityRates
Other,mortalityRates
Other,most
Adult,mostCommonAdultCancersInKenya
Utilized,mostCommonAgentsUsedInBreastCancerTreatment
Other,mostCommonCancer
Other,mostCommonCancerInWomen
Cohort,mostCommonCancerOfAdolescentsAgedAccountingFor56PercecntOfInvasiveBreastCancerInWomen
Other,mostCommonMalignantTumor
Other,mostCommonNeoplasms
Other,mostCountries
Actual,mostEffectiveTechniqueused
European,mostEuropeanCountries
Predominant,mostFrequentCancerInWomenTreatedWithHormonalTherapy
Other,mostFrequentlyDiagnosedCancer
Other,mostFrequentlyOccurringCancer
Predominant,mostFrequentMalignancy
Other,mostInvasiveDisease
Paraneoplastic,mostLikelyParaneoplastic
Nondestructive,mostNondestructiveTests
Other,mostPatients
Caregiver,mostPervasiveTypeOfCancerAmongWomen
Other,mostPowerfulTool
Preterm,mostPretermBirth
Global,mostPrevalentMalignancyAmongWomenAroundWorldAreDiagnosedYear
Predominant,mostPrevalentMalignancyDiagnosedInPregnancy
Predominant,mostPrevalentType
Danger,mostProminentCause
Other,mostRelevantKind
Stigmatization,mostStigmatization
Other,mostWomen
Other,MP
16,mPatients
Other,MRI
Other,mriImaging
Ecchymosis,mrnaExpressionLevelOfPcdh10
MSOT,MSOT
MSOT,msotImaging
16,mStage
Food,mtorInhibitorEverolimus
Focus,muchFocus
Focus,multicenterStudy
Quantification,multidimensionalScaling
Interference,multidisciplinaryAssessment
Restoration,multidisciplinaryCare
Other,multigenePanels-with
Strategy,multimodalityTreatmentStrategy
Other,multimodalTherapy
Other,multipleBiological
Aberrances,multipleGeneticAberrances
Solicitations,multipleSolicitations
Multiplex,multiplexAssay
Discovery,multiplexedAssayForDetectionOfAutoantibodiesInCanineTumours
Description,multiresolutionResult
Multi-stimuli-responsive,multi-stimuli-responsiveTheranosticNanoplatform
Other,multivariate
Cox,multivariateCoxProportionalHazardRegressionAnalysis
Focused,multivariateModelsAdjustedForIncome
Adult,multiyearCollaborationLedByUnionForInternationalCancerControl
Antibody,murineMonoclonalAntibodies
Necessity,mustAddressed
Necessity,mustAddressedDuringCancerGeneticCounselingConsultations
Personalized,mustIndividualized
Restoration,mustIndividualizedWithEmphasisOnOptimalCareOfMother
Spouse,mutationalStatusBesidesFamilyHistory
Hybrid,mutationEvents
Hybrid,mutationRatio
Mutations,Mutations
Other,myeloperoxidase
Other,NAC
Other,nano-biosensor
Nanocarrier,nanocarrier
Nano-genosensor,nano-genosensor
Nanoplatform,nanoplatform
Other,nationwideRegistries
Other,nature
Other,navigationSurgery
Gene,NCAM1
Necessity,necessary
Necessity,necessity
Necessity,need
Required,needed
Restoration,neededAcrossCareContinuumEspeciallyInLow-resourceSettings
Necessity,needForAnalysisOfMetastaticTissuesAtRecurrence
Mimics,needForAwarenessOfMimicsOfBoneMetastasis
Situations,needForNodalRadiotherapyInSpecificSituations
Prevention,needsInPrevention
Other,negativeEffects
LVEF,negativelyCorrelatedWithLvef
Other,negativeMargins
Other,neglected
Nek6,Nek6
Ecchymosis,nek6Expression
Radiotherapy,neoadjuvantChemotherapy
Radiotherapy,neoadjuvantChemotherapyGroups
Herceptin,neoadjuvantChemotherapyWithHerceptin
Neoadjuvant,neoadjuvantSetting
Neoadjuvant,neoadjuvantTreatment
Other,neonatal
Number,neonatalOfRetrospectiveCohortOfPregnantWomenWith
Disease,neoplasms
Adult,netherlandsCancerRegistryOf37230PatientsWithEarlyBreastCancer
Resistance,netvizzApplication
Network,networkOutput
Other,networks
Hybrid,neuralNetworkClassifier
Neuroma,neuroma
Other,neutralEffects
Proportion,neutrophil-to-lymphocyteRatio
Intrapulmonary,newBilateralIntrapulmonaryNodules
Purpose,newDesignDouble-layerCapacitors
Interference,newerDrugDeliveryStrategies
Restoration,newOpportunitiesForDevelopmentOfNovelTherapeuticStrategies
Other,news
Other,newSpecificMarkers
Regimens,newTreatmentRegimens
Other,nextMade
Ecchymosis,nf-krab-inducedIncreasedExpressionOfCcnd1
Mood,nippleAreolaComplexInvolvement
Nonparticipation,nippleInvolvement
Strategy,nirFluorescenceImagingSystem
Filter,nirProbe
Other,NLR
Other,NMA
Other,nodalMegakaryocytes
Exposure,nomogram
Other,non-coverage
Testing,nondestructiveTesting
Nondestructive,nondestructiveTests
Other,non-ideal
Other,noninvasive
Other,noninvasiveImaging
Technique,noninvasiveImagingTechniqueForBreastCancerDiagnosis
Other,Non-linearity
Users,non-nsaidUsers
Nonparticipation,nonparticipation
Focus,non-sentinelLymphNode
Hazard,non-standardLessPromptTreatmentsIrrespectiveOfComorbiditiesWithIncreasedRiskOfMortality/relapse
Treatments,non-standardPromptTreatments
Purpose,normalCardiacFunction
Other,normalDucts
Other,normalSamples
Other,normalTissues
Other,notablyDesigned
Other,noted
Odds,noticeableDrugLoadingCapacity
Other,novelInsightsIntoPotentialMechanismsAssociatedWithBreastCancerPathogenesis
Other,novelMethod
Other,novelNavigationSurgery
Filter,novelNear-infraredNirFluorescentProbe
Technique,novelPowerfulTechnique
Symptom,novelStrategiesForDiagnosisOfBreastCancerWithHyperglycemia
Targeted,novelTargetedTherapeuticOptions
Targets,novelTherapeuticTargetsFor
Other,novelty
Utilized,nowAlsoWidelyUsed
Danger,nsaidExposure
NSAIDs,NSAIDs
Danger,nsaidsExposure
NSAID,nsaidUsers
Other,nslnMetastasis
V-G,n-typeVoltage-gatedV-gCalciumChannelBindingAntibodies
Atypia,nuclearAtypia
Species,nudeMice
Number,number
Number,numberVariants
Numerous,numerousGene-expression-basedPrognosticSignatures
Disease,obesity
Obesity,Obesity
Purpose,objective
Purpose,objectiveResponseRate
Other,objectives
Other,obscure
Other,observationalStudies
Other,observations
Other,observed
Obstetrician,obstetrician
Obstetricians,obstetricians
Other,obtained
Other,obtainedFeatures
Distinct,obtainedFrom66FemalePatientsWithMAtDifferentTimeIntervalsForEvaluationOfCtcsByFlowCytometry
Other,obtainedFromPatientsWithBreastCancer
Other,occultBreastTumors
Other,occurrence
Other,occurrenceOfBreastCarcinoma
Other,occurring
Other,occurringCancers
Odds,odds
Other,oedema
Alpha,oestrogenReceptorAlpha
Other,oestrogenReceptorCofactors
Other,oestrogenReceptorPositiveIn58PercecntOfCasesPositiveIn62Percecnt
Of121,of121Patients
Other,offered
Debated,oftenDebated
Hypomethylated,oftenHypomethylated
Other,oftenRelated
Symptom,oftenWellScrutinisedByPathologistsForEvidenceOfMetastaticCarcinomaAsImportantPrognosticParameterInStandardSetting
Other,old
Other,olderWomen
Chemical,omega3FattyAcids
Acids,omegaFattyAcids
Other,omission
Other,oncogenes
Other,oncogenesEsr1
Restoration,oneExtraVisit
Hybrid,oneMutation
Other,oneRandomlyAssignedToAxillaryDissection
Other,oneRegion
Other,oneRegionAnother
Testing,oneScreeningProgramme
Other,onEsophagogastroduodenoscopyIdentifiedInAntrum
Subtype,oneSpecificSubtype
Other,one-waySensitivityAnalyses
Other,ongoingTrials
Specimen,only1ulOfSerumSample
16,only20Percecnt
Other,only35Cases
Neuromas,only35CasesOfTraumaticBreastNeuromas
Other,only44Percecnt
Subgroup,onlySubgroupWithProgesteroneReceptor
Other,onlyWomen
Other,Ontario
Other,OP
Biopsy,openBiopsyOfNodularityAttachedToPectoralMuscleFascia
Other,operablePatients
Other,opportunities
Other,opticalAbsorptions
Other,opticalCoherenceTomographyImages
Intensity,optimalCut-offValue
Values,optimalCutoffValues
Benchmark,optimalTherapeuticTargetForPatientWithAdvancedBreastCancer
Other,options
Other,OR
Other,organotropic
Other,ORR
Disease,OS
OS,osAdvantage
Proliferation,osteopontin-750Accumulation
Filter,osteopontin-basedProbe
Osteopontin,osteopontinPeptide
Evolve,otherAgeGroups
Accumulation,otherData
Other,otherDietaryRecommendations
Other,otherInotherTertiaryCentres
Considerable,otherSignificantConcerns
Sites,otherSites
Subtypes,otherSubtypesOfBreastCancer
Purpose,ourAim
Other,ourBreastCancerPatients
Food,ourExperience
Food,ourExperienceOfHigh-doseRadiotherapy
Restoration,ourFacility
Other,ourFindings
Testing,ourLiteratureReview
Result,ourPatient
Distinct,ourPreviousWorkRegardingToPropertiesOfPluronicsWithDifferentPhotosensitizerForPhotodynamicTherapy
Other,ourResults
Focus,ourStudy
Testing,ourTheoreticalAnalysis
Hazard,outcome
Intensity,outcomeInEr-positive/humanEpidermalGrowthFactorReceptorType2-negativeBreastCancersWithHighHazardRatiosIndependentlyOfOtherMarkers
Hazard,outcomeInLymphedemaPatients
Other,outcomes
Other,outcomesOfEstrogenReceptorPositive
Other,outliers
Ovarian,ovarianCancer
Intensity,overallLowOfSixCirculatingMirnas
Survival,overallMedianSurvival
Other,overallMediumSecondTumor-freeTime
Disease,overallSurvival
Other,overexpressed
Other,overexpression
Overexpression,Overexpression
Other,overnight
Other,over-represented
Other,overview
Actual,oxidationPeakCurrent
Alpha,P
Alpha,pLessThan
Other,painless
Other,painlessLumpInBreastAccountingFor688PercecntOfPatients
Other,pairedTumor
Other,pairedUntreatedPrimaryTumor
Gene,PALB2
Radiotherapy,palliativeChemotherapy
Membrane,panel
16,panelOf25GenesInvolvedInMechanismsOfTargetedTreatmentResistanceIn16PrimaryBreastCancersDevelopedDuringTreatment
Distinct,panelOfCellLinesWithDifferentPhenotypes
Restoration,panelOfMonoclonalAntibodiesAgainstNewlyEstablishedCellLine
Output,paper
Parameters,parameters
Other,parameterUncertainty
Antibody,paraneoplasticAntibodyPanel
Disease,paraneoplasticNeurologicSyndromes
Other,parpInhibitors
Considerable,partialPathologicalResponseWithLargeAreasOfTumourRegression
Species,participants
Participants,participantsWithBreastCancer
Basis,particular
Intensity,particularEmphasisQuantifying
Other,pathogenesisOfBreastCancer
Other,pathogenic
Pathogenic,pathogenicVariants
BRCA1/2,pathogenicVariantsInBrca1/2
Pathologically,pathologicallyTumor-freeNodes
Pathologic,pathologicalResults
Pathologic,pathologicalSpecimen
Pathologic,pathologicEvaluation
Obstetrician,pathologistAnnotation
Other,pathologists'Awareness
Testing,pathologyForFurtherFollow-up
Other,pathway
Species,patient
Food,patientEducationIdentification/reportingOfSideEffects
Other,Patients
Species,patients
Other,patientsByTrastuzumab-pretreatment
Bromide,patientSelectionForNon-pcosReferenceCohort
Testing,patient'sMedicalHistory
Testing,patients'MedicalRecords
Other,patientsOnAromataseInhibitors
Other,patients'Prognosis
Other,patients'Self-monitoring
Weight,patient'sTumorBurden
Other,patientsWithBreastCancer
Other,patientsWithBreastCancerReceivingWithAnthracyclines
HER2,patientsWithHer2
Ecchymosis,patientsWithHer-2PositiveExpression
Other,patientsWithHistoryOfBreastSurgery
Provider,patientsWithHumanEpidermalGrowthFactorReceptor2
Locoregional,patientsWithLocoregionalInSouthernPortuguese
16,patientsWithMAmongThem
Other,patientsWithMeasurementErrors
Other,patientsWithMetastaticBreastCancer
Other,patientsWithNeoplasticDisease
Benchmark,patientsWithReducedBaselineLvef
PA,paTreatment
Other,pattern
Other,patterns
Subgroup,patternsOfAssociationResults
Susceptibility,pb-ctMode
Gene,PCDH10
PCDH10,pcdh10GenePromoterMethylationIdentifiedInDuctalCarcinoma
Disease,PCOS
PCOS,pcosGroups
Other,pCR
Other,pcrResults
Other,pcrThanWomenWithHr-positiveTumors
Hybrid,pD1542yMissenseMutation
Axis,pdgfs/pdgfrsAxis
Hazard,peakInRecurrenceRisk
Pearson,Pearson
Pearson,pearson'sR
Isolation,penalizedLogisticRegression
Other,percecnt
Other,percecntConfidenceIntervals
Other,percecntRelapsedTissues
Percent,percent
Restoration,perceptionOfQualityOfCareProvidedByCancerCareNetworkForEarlyDetectionOfBreastCancer
Exposure,performance
Exposure,performanceEvaluation
Other,performed
Other,performedFromInceptionToJanuary312018
Young,performedInFemaleParticipantsWithBreastCancerFromJune2015ToDecember2017
Interval,period
Bromide,periodOfObservation
Periods,periods
Cohort,peripheralBlood
Cohort,peripheralBloodSamples
Decision-making,personalDecision-making
Subjective,personalGoals
Subjective,personalGoal-setting
Personalized,personalizedFollow-upSchemes
Other,perturbation
PFS,PFS
Other,pH
Parameters,pharmacokineticParameters
Phenotype,phenotypeExpression
HER2,phForHer2AgainstHer2-overexpressedBreastCancer
Phosphorylation,phosphorylation
Phosphorylation,phosphorylationOfAkt
Conflict,physicalActivity
Conflict,physicalActivityInPatientsWithMetastaticBreastCancer
Adult,physicallyActive
Other,physician
Other,PI3K/AKT/mTOR
Other,pi3k/aktSignaling
Description,picture
Focus,place
Other,planning
Levels,plasmaLevels
Platform,platform
Other,pleuralDiseaseProgression
Disease,pleuralMetastasis
Pleurodesis,pleurodesis
Pleurodesis,pleurodesisForMalignantPleuralEffusion
Testing,PM
Strategy,policyActions
Disease,polycysticOvarySyndrome
Other,pool
Cohort,poor
Cohort,poorAdhesion
Hazard,poorerOutcome
Other,poorerPrognosis
Other,poorerPrognosisInWomenWithBreastCancer
Cohort,poorPrognosis
Other,popular
Subgroup,population
Other,population-basedStudies
Other,Porto
Other,portugueseInstitute
Other,portugueseWomen
Other,positive
Other,positiveChanges
Susceptibility,positiveChangesInTheirHealthBehaviours
Other,positivelyAssociated
Other,positivelyCorrelated
Amplification,positiveRegulatoryFeedbackLoopForFxyd3Amplification
SLN,positiveSln
Other,positiveTreatment
Other,possibility
Evolve,possibleCorrelationsWithClinicalStatusIncludingAge
Interference,postAssessment
Nucleus,posteriorFossaOfBrain
Postmenopausal,postmenopausalPatient
Other,postmenopausalwomen
Restoration,postmenopausalWomenWithDevelopmentOfBreastCancer
Post-NAC,post-NAC
Levels,post-nacBpeLevels
Interference,postOperativeAssessment
Other,postoperativeComplications
Other,postponementVisiting
Other,potential
Resistance,potentialApplicationForDiagnosisOfCancerInFuture
Other,potentialBiomarkerForCancerDiagnosisThanMrnaBiomarkers
Collision,potentialImpact
Fertility,potentialImpactOnFertilityAfterTreatment
Other,potentialImportanceAsModelsForHumanBreastCancer
Mechanism,potentialMechanism
Mechanism,potentialMechanismForFoxc1-inducedMetastasis
Actual,potentialOfAionAsEffectiveMultimodalContrastAgentForBreastCancerDiagnosis
Benchmark,potentialTarget
Benchmark,potentialTherapeuticTarget
Strategy,potentialTreatmentStrategy
Endocrine-resistant,potentialTreatmentStrategyForEndocrine-resistantBreastCancers
Gene,PR
Radiotherapy,practicalImplicationsOfOngoingChemotherapy
Caregiver,practitionerDecisionmaking
Other,practitionersKnowledgeable
Other,pre
Distinct,preciseToolForTargetedTreatmentOfCancerIncluding
Other,precision
TAMs,preclinicallyTams
Other,preclinicalModels
Other,preclinicalPhase
Other,pre-diagnosticObesity
Description,prediction
Predictors,predictors
Predominant,predominant
Other,pregnancy
Other,pregnancyFrom1959To1966
Other,pregnancyOutcomes
Subset,preliminaryGroupOfCtibl
Other,premenopausalPatients
Interference,preoperativeAssessment
Interference,pre-operativeAssessment
Other,preoperativeCytologicalDiagnosisOfBreastCancerMetastasesInRegionalLymphNodesIn84Patients
Other,preoperativeDiagnosis
Will,preoperativeUnderstanding
Other,presence
Contribution,present
Presentations,presentations
Other,presented
Number,presentedWorkForFeatureExtraction
Ecchymosis,preservationOfBiomarkerExpressionInOldFfpeTumour
Disease,pretermBirth
Odds,prevalenceOfobesityOf277Percecnt
Prevention,prevention
Estrogen-alone,preventionOfDiagnosedBreastCancerInEstrogen-aloneArmOfWhi
Testing,previousCervicalCancerScreening
Other,previousStudies
Restoration,primaryCareProvider
Testing,primaryPurposeOfPeriodicMammogramsInScreeningProgramsIs
Disease,primaryTumor
Other,primaryTumours
Prior,priorMedicalHistory
Susceptibility,proactiveManagementOfPsychologicalHealth
Entry,probablyTranscriptionalActivation
Filter,probe
Other,Probes
Other,problem
Other,procedure
Other,processes
Other,processing
Other,product
Other,profile
Cohort,prognosesOfYoungMenWithBreastCancer
Other,prognosis
Township,prognosisOfPatientsWithMaleBreastCancerInShanxiProvinceOfChinaFrom2007To2016
Other,prognostic
Provider,prognosticFactorIndependentOfOtherClinicalVariables
Ecchymosis,prognosticMeritOfNek6ExpressionInBreastCancer
Proportion,prognosticSignificanceOfNeutrophil-to-lymphocyteRatioInPatientsWithBreastCancer
Other,prognosticSignificanceOfNlrInEarlyStage
Other,prognosticStagingSystems
Intensity,prognosticValue
Other,program
Other,progressionDisease
Survival,progression-freeSurvival
Spread,progressionOfTumorInvasionInBreastCarcinoma
Other,prohibitivelyExpensive
Proliferation,proliferation
Proliferation,proliferationOfCells
Proliferation,proliferationOfMcf-7Cells
Other,promising
Prior,promisingShort-termStrategiesPriorToTreatmentAdministration
Supplements,promisingSupplements
Benchmark,promisingTherapeuticTargetForBreastCancer
Other,promoterMethylationInCertainTypesOfHumanTumors
Other,promoterMethylationStatus
Propagation-based,propagation-basedPhase-contrast
Propensity,propensityScoreMatchingAnalysis
Other,properAccessToDiagnosis
Other,properImaging
Other,properties
Intensity,proportion
Other,proposed
Other,proposedAlgorithm
SPD,proposedCovariance-basedSpdMatrices
Other,proposedForBreastTumorGrading
Other,proposedMethod
Adulthood,prospectivelyFollowedFor3YearsSinceDiagnosis
Focus,prospectiveNestedCase-controlStudy
Other,prospectiveStudies
Other,protected
Other,protective
Provider,protectiveFactor
Factors,protectiveFactors
Purpose,protectiveRoleOfRs5743810
Ecchymosis,proteinExpression
Ecchymosis,proteinExpressionOfNf-krab-p65
Other,proteinKinase
Other,proteinS-100
Gene,Protocadherin-10
Protocols,protocols
Other,psychologicalAspects
Cohort,public
Restoration,publicHealthCareSystem
Description,publicHealthChallenge
Pure,pureDcis
Pure,pureDcisInClinicopathologicCharacteristics
Purpose,purpose
Other,q12X
Other,quadrantectomy
Other,qualitativeApproach
Intensity,quality
Intensity,qualityEvidence
Intensity,qualityOfLife
Survivors,quality-of-lifeFactorsForSurvivorsIncludingSexualDysfunction
Intensity,qualityOfLifeOfPatients'Spouses
Quantification,quantification
Parameters,quantitativeParameters
Other,quantitativeRealTimeFluorescencePolymeraseChainReaction
Other,queried
Description,questionnaireBasedOnAnderson'SdelayModel
Alpha,r
Coefficient,R
Other,racialDisparity
Survival,radiation
Other,radiationTherapy
Other,radioisotope
Other,radiologicalSignsOfMalignancy
Radiomics,radiomics
Radiomics,radiomicsScore
Other,Radiotherapy
Radiotherapy,radiotherapy
Description,randomEffectsModel
Random-sampling,random-samplingMethod
Other,ranging
Mood,rangingFromDiagnosisPhaseToControlOfDisease
Gene,RANKL
Other,rapidBreast-cancer-tissueDiagnosis
Other,rare
Presentations,rareClinicalPresentations
Presentations,rarePresentations
Other,rareTumor
Percent,rate
Other,rates
Proportion,ratio
Benchmark,rationaleForTamsAsTherapeuticTargetInBreastCancer
Disease,RDD
Other,reality
Actual,realNeedOfSurgicalTreatment
Other,real-time
Other,real-worldSetting
Other,receivedWithoutSurfaceModification
Positivity,receiverOperatingCharacteristic
Positivity,receiverOperatingCharacteristicCurves
Focus,recentDanishCohortStudy
Other,recentDevelopments
Other,recentEpigenomeStudies
Other,recentlyDiagnosedBreastCancer
Utilized,recentlyHaveUsedAsBiomarkers
Other,recentStudies
Adulthood,recentYears
Other,receptorActivator
Other,recognized
Considerable,recognizedAsCtcIn1Of15HealthyBloodSamples
Other,recognizingMethylationStatus
Other,recommendations
Other,recommended
Other,recurrence
Other,recurrence-free-survival
Other,Recurrences
Collision,recurrentWords
Benchmark,reducedBaselineCardiacFunction
Benchmark,reducedBaselineLvef
Bromide,reference
Bromide,referenceForClinicians
Other,referral
Other,Referrals
Isolation,regression
Description,regressionModel
Isolation,regressionModels
Other,regulated
Other,regulationOfNras
Other,relapse
Relapse,relapseRates
Other,related
Testing,relatedResearchDataOfDiagnosisOfInoperableLocallyAdvancedBreastCancer
Provider,relatedTranscriptionFactorSox9
Other,relation
Other,relationship
Other,relationshipBetweenNlr
Ecchymosis,relationshipBetweenStromalExpressionOfPodoplaninInInvasiveBreastCarcinoma
Restoration,relativelyGoodPrognosisWith5YearOverallSurvivalOf88Percecnt
Relative,relativeThose
Postmenopausal,relativeThoseOfPostmenopausalPatients
Will,releaseFromSerumStarvationInMcf-7Cells
Will,releaseProfile
Other,relevant
Other,remarkableImprovements
Other,repair
Replaced,replaced
Other,report
Other,reported
Reporter,reporterAssays
Bayes,reportOnPerformanceOfBayesClassifiersLikeTreeAugmentedNaiveBayes
Other,represented
Required,required
Testing,research
Other,researchers
Researchers,Researchers
Discovery,researchLight
Other,Residents
Nonparticipation,resistance
Nonparticipation,resistanceToMultipleTypesOfTreatmentInBreastCancerModels
Other,resistant
Other,resonanceImaging
Other,resources
Other,respectivelyFound
Other,respondents
Signature,response
Signature,responseRate
Other,responsible
Other,responsibleMechanisms
Restoration,restoration
Description,result
Description,resultCompatibleWithMetastasisToOrbit
Description,resultOfPreviousOrbitalBiopsy
Other,Results
Other,resultsDiagnosed
Focus,resultsOfStudy
Other,Resurgery
Other,retrieved
Other,retrospective
Focus,retrospectiveObservationalStudyOf264Her2-positiveAdvancedBreastCancer
Other,retrospectiveStudies
Focus,retrospectiveStudyOfWomenTreatedWithTrastuzumabForHumanEpidermalGrowthFactorReceptor2BreastCancerAtMayoClinicBetweenJanuary12000
Revealed,revealed
Considerable,reverseActiveLearningForClassificationOfHealthyBreastTissue
Inverse,reverseTranscriptionQuantitativePolymeraseChainReaction
Reverse,reverseTranscription-quantitativePolymeraseChainReaction
Testing,review
Strategy,revisionsOfAjccBreastCancerStagingSystem
Other,ribonucleotideReductaseM2
Robust,richSpectralFeaturesOfPhenyboronicAcid-basedNanoprobe
Focus,rightMastectomyWithSentinelLymphNodeBiopsy
Hazard,Risk
Distinct,risk/benefitOfDifferentTreatmentModalities
Provider,riskFactor
Provider,riskFactorForLung/bronchusCancer
Hazard,riskFactors
Hazard,riskFactorsOfLvi
Testing,riskFactorsOfLviByMultivariateAnalysis
Hazard,riskForRecurrence
Adulthood,riskOfBreastCancerInAdulthood
Conflict,riskOfDeath
Restoration,riskOfDevelopmentOfGliomas
Hazard,RiskProtection
Other,risks
Late-stage,risksOfLate-stageDiagnosis
Hazard,riskStratification
Strategy,risk-stratifiedScreeningStrategy
Other,rituximab
RL,RL
Other,rnaKnockdown
Oligonucleotides,rnaOligonucleotides
RNAs,RNAs
Testing,rnaSequenceAnalysis
Robust,robust
Other,robustSynthesisMethods
Robust,robustTechnology
Purpose,role
Purpose,roleOfAutoantibodiesInEarlyCancerDiagnosis
Purpose,roleOfEstrogens
Phenotype,roleOfImage-basedTextureFeaturesAsNoninvasivePrognosticBiomarkers
Purpose,roleOfPdgf-b/pdgfr-betaAxisInRareTypesOfBreastCancers
Caregiver,roleOfPrimaryCaregiver
Purpose,roleOfSupportOfferedByVirtualCommunitiesToBreastCancerPatients
Restoration,rolePlayedByPdgfFamilyMembersInNormalDevelopmentOfBreastTissueDespiteItsPotentPro-lymphangiogenicEffects
Other,roles
RON,RON
Learning,ronInternalization
RON,ronReceptorTyrosineKinase
RRM2,RRM2
Ecchymosis,rrm2Expression
Mutation,rs5743810
Allele,rs5743810ProAllele
Restoration,rural-basedTertiaryCancerCareCenter
Other,ruralCancerHospital
Other,ruralSetting
Alpha,S
Other,S+RT
Other,safety
Subset,sameRangeAsCasesWithoutWavelength-dependentMeasurementErrors
Specimen,sample
Other,samples
Satisfied,satisfied
Arabian,saudiArabianWomen
Scalable,scalable
Scalable,scalableIntervention
Testing,scan
KDM4B,scffbxo22-mediatedKdm4bDegradation
Other,scope
Other,score
Other,screened
Other,Screening
Testing,screening
Testing,screeningBehavior
Testing,screeningPrograms
Strategy,screeningStrategy
Testing,screeningTools
Other,scrutinised
Other,scrutinized
Other,SD-CNN
SE,SE
Testing,search
Other,secondary
Proliferation,secondaryConfirmationOfSignalAccumulationUsingNearInfraredFluorescentImaging
Lymphedema,secondaryLymphedema
16,secondDecadeAfterDiagnosis
Other,secondLargestHmo
Danger,secondLeadingCause
Other,secondSurgery
Other,secondTumor
Other,secretion
Provider,secretionOfTumorNecrosisFactor
Other,seen
Other,segmentationAlgorithm
Other,selectedPatients
Treatments,selectedStandardTreatments
Osteopontin,selectiveAccumulationOfFluorescentOsteopontinInVitroAndInVivo
Binding,selectiveBinding
Sensitive,sensitive
Sensitive,sensitiveNano-genosensor
Other,sensitivity
Other,sensitivityOf786PercecntRespectively
Other,sensor
Focus,sentinelLymphNode
Focus,sentinelLymphNodeBiopsy
Focus,sentinelNodeBiopsy
Other,sentinelNodes
Learning,separateClassificationModels
Other,sequencing
Other,serious
Other,serumSamplesFromCancerPatients
Values,seValues
Seven,sevenWomen
Techniques,severalIntelligentTechniques
Other,severalObjectives
Genes,severalOtherGenes
Other,severalPatients
Disease,sexualDysfunction
16,sexualStigmatizationOfM
CNN,shallowCnn
Other,shallow-CNN
Township,shanxiProvinceOfChina
Formed,shaped
Other,shapes
SNVs,sharedSnvs
Other,she
She,She
16,shorterIntervalsBetweenD
Regimens,shorterRadiotherapyRegimens
Strategy,short-termStrategy
Other,shouldCo-managed
Obstetrician,shouldCo-managedByCardiologist
Other,shouldElaborated
Other,shouldKept
Resistance,shouldOvercomeBeforeClinicalApplication
Other,shouldPerformed
Hazard,shouldPerformedInAtRisk
Other,shouldProceede
Pure,shouldProcessed
Other,shouldStaged
Other,show
Other,shown
Complex,sialicAcidExpression
Areola,sideEffects
Areola,sideEffectsOfBreastCancerTherapiesIncludingHotFlushes
Amplification,signalAmplificationStrategies
Intensity,signalIntensity
Signature,signature
Signatures,signatures
Other,significance
Other,significanceLevel
Other,significanceOfTime-trends
Considerable,significant
Considerable,significantAdvances
Considerable,significantAssociationBetweenLevelsOfNek6
Considerable,significantAssociationBetweenRs5743810AllelicFrequency
Considerable,significantCausativeGenes
Considerable,significantChallenge
Conflict,significantDifference
Considerable,significantHigherRisk
Considerable,significantIncrease
Other,significantlyAssociated
Other,significantlyCorrelated
Survival,significantlyCorrelatedWithOverallSurvival
Intensity,significantlyCorrelatedWithTumorSize
Reduced,significantlyDecreased
Other,significantlyHigher
Benchmark,significantlyHigherBaselineBpeLevelsThanPostmenopausalWomen
Other,significantlyHigherPcrRatesThanPatientsWithLuminalTypes
PFS,significantlyProlongedMedianPfs
Reduced,significantlyReduced
Other,significantlyUp-regulated
Other,significantlyYounger
Evolve,significantlyYoungerAge
Other,similar
Parameters,similarExperimentalParameters
PFS,similarPfs
Adverse,similarSeriousAdverseEvents
Factors,similarTendencyRelatedWithPrognosticFactors
Filter,similarTowaveletFilter
Simulated,simulatedBreastCancer
Simulated,simulatedInnerBreastTissue
Other,single-cellWhole-exomeSequencing
Other,singleMetastaticSite
Variants,single-nucleotideVariants
Sites,sites
Binding,site-specificBindingLeadingToImprovedCancerTreatmentWithMinimalRisksToNormalCells
Circulating,sixCirculatingMirnas
Sites,sixGlycosylationSites
Kazakhstan,sixteenRegionsOfKazakhstan
Disturbances,sleepDisturbances
Biopsy,slnBiopsy
SLN,slnMetastasis
Reduced,small
Other,smallerMyeloperoxidase
Reduced,smallMoleculeInhibitors
Reduced,smallPopulation
Intensity,smallProportion
SNPs,SNPs
SNVs,SNVs
BRCA1,soFarHasMainlyAssociatedWithMutationsInBrca1
Solicitations,solicitations
Other,solidTumors
ST-2,solubleSt-2Level
Other,sometimesMistaken
Other,southernPortuguese
Gene,SOX9
Nucleus,sox9NucleusEntry
Other,SP
Other,sparseCoding
Axis,sparseCombinationOfRiemannianDictionaryAtoms
Alpha,sParticipants
Other,SpCM
SPD,spdMatrices
Caregiver,specialType
Nonparticipation,specificallyPlacedOnInflammatoryBreastCancerWithSkinInvolvementOnCutaneousMetastasesToBreastFromBreastCancer
Components,specificCancerCell-relatedComponents
Other,specificCircumstances
Filter,specificEralpha-targetedProbe
Food,specificFoodRecommendations
Other,specificGroups
Subtype,specificSubtype
Specimen,specimen
Other,spectrum
Odds,speed
Other,spindleCells
Other,splenicLymphocytes
Spouse,spouse
Spouses,Spouses
Other,SRC
Aptamer,ssdnaAptamerMf3
ST-2,st-2Level
Other,stable
Entry,stableBodyWeight
Binding,stableDrug-carrierBinding
Other,stage
Other,stageI/iiaCases
Other,stageIi
Other,staging
Other,stagingSystems
Other,staining
Other,standard
Testing,standardBiomarkerTestingByImmunohistochemistry
Subgroup,standardizedDataCollection
Other,standardMethod
Other,standardMethodForEvaluationOfProposedPrognosticTumourMarkers
Restoration,standardOfCareAsFirst-lineTreatmentOfPatientsWithHer2-positiveAEvenInReal-worldSetting
Restoration,standardOfCareForBreastCancer
Gene,STAT1
Output,stat1RecruitmentToEralphaPromoterRegion
Other,state-of-the-artAlgorithms
Subgroup,statisticalAssociation
Other,statisticalClassifiers
Other,statisticallyCorrelated
Considerable,statisticallySignificantValuesAt4Cells/7MlBlood
Other,status
Other,Stem-likeCells
Steps,Steps
Biopsy,stereotacticWire-guidedBiopsy
Stigmatization,stigmatization
Elusive,stillDifficult
Other,stillObscure
Numerous,stillSeriousHealthProblemIn21stCenturySubjectToManyResearch
Strategy,strategy
Other,stratification
Evolve,stratifyingForAge
Ecchymosis,stromalExpression
Robust,strong
Robust,strongAssociationBetweenRs5743810AgainstRiskInSaudiArabianWomen
Conflict,strongContrast
Conflict,strongContrastWithImagingModalities
Robust,strongIndependentPrognosticFactor
Other,stronglyPositive
Restoration,structureChanges
STs,STs
STs,stsOfDeath/relapse
Other,studies
Focus,study
Focus,study'sObjectives
Subgroup,subgroupVariables
Subjective,subjectiveRisk
Entry,subsequentCancerCounselingOfFemaleSurvivors
Lung/bronchus,subsequentLung/bronchusMalignancies
Other,subsequentlyAssessed
Subsequent,subsequentMalignancies
16,subsequentMalignanciesForLung/bronchusCancerWith13PercecntSurvivorsSufferedFromSubsequentMalignancies
Subsequent,subsequentPrimaries
Radiomics,subsequentRadiomics
Subset,subset
Considerable,substantialDiscordancesBetweenPrimaryTumors
Considerable,substantialImprovements
Subtype,subtype
Subtyped,subtyped
Subtypes,subtypes
Subtype-specific,subtype-specificPrognosticSignatures
Signature,subtype-specificSignature
MiRNA-21,successfulFunctionalizationOfNanocompositeOfSpecificSequenceOfAminatedComplementaryOligonucleotideOfMirna-21
Quantification,successfulQuantification
Quantification,successfulQuantificationOfCa15-3InSerumSamplesFromCancerPatients
Distinct,successOfSymmetricPositiveDefiniteMatrices
Intensity,suchLowIncidence
Other,suchStandardization
Other,suchSymptoms
Caregiver,sufferingFromWoman'sDisease
Other,suggested
Other,sulass
Other,summary
Hazard,summaryHazardRatios
Supplements,supplements
Other,support
Binding,supportVectorMachine
Cytology,surfaceMorphology
Other,surgery
Craniotomy,surgicalExcision
Craniotomy,surgicalExcisionWithRadiation
Restoration,surgicalImplantationReconstruction
Mood,surgicalOptionsIncludingPreservationOfNippleAreolaComplex
Hazard,surgicalOutcome
Other,surgicalOutcomes
Accumulation,surveillanceData
Accumulation,surveillancePopulation-basedData
Other,Survival
Survival,survival
Accumulation,survivalData
Survival,survivalDifferences
Other,survivalDistributions
Description,survivalPrediction
Percent,survivalRate
Survival,survivalRates
Survival,survivalThanAdjuvantTherapy
Survival,survivalVariance
Other,suspected
Other,sustainedStableDisease
Other,suutaneousBreastTumor
Ecchymosis,suutaneousEcchymosis
Other,suutaneousLymphaticChannels
Other,suutaneousLymphaticChannelsInReal-time
Other,SUVmax
Other,SVM
Other,SVM-BRC
Other,switch
Switched,switched
Symptom,symptom
Food,symptomaticHeartFailure
Other,symptomaticWomen
Symptom,symptomBurden
Other,symptoms
Survival,synchrotronRadiation
Syndrome,syndrome
Syndromes,syndromes
Other,synonymous
Other,synthesisMethods
Other,synthesized
Strategy,system
Radiotherapy,systemicChemotherapy
T2,T2
TAAs,TAAs
Other,tackled
Other,taiwanLongitudinalHealthInsuranceDatabase2005
TAM,TAM
Chemical,tamoxifen
Nonparticipation,tamoxifenResistance
Other,tamoxifen-resistanceInErCancerCells
TAMs,TAMs
Other,tangshanPeople
Other,tanUsage
Benchmark,target
Other,targetedTherapies
Targeted,targetedTherapies
Other,Targeting
Other,targetingFxyd3-mediatedPathway
Benchmark,targetRelationshipBetweenDscam-as1
Targets,targets
TBR,TBR
Other,team
Technique,technique
Techniques,techniques
Other,tendency
Cross-validation,tenfoldCross-validationMatthew
Learning,termsOfClassification
Other,termsOfKyotoEncyclopediaOfGenes
Mechanism,termsOfMechanism
Susceptibility,tertiarySexualHealthCenters
Other,tested
Testing,testing
Testing,testingDatasetsCollectedFrom48Patients
Other,tests
Texture,textureAnalysis
Phenotype,textureFeatures
Subset,thanCapecitabineGroup
Other,thanDcis
Other,that
Subset,thatInMabaGroup
Subset,thatInNon-pcrGroup
MiR-511,thatOfMir-511
Other,thatOfOtherCountries
Other,the
Other,their
Positivity,theirAbility
Originally,theirAbilityOfPrognosisPredictionInTheirOriginallyTargetedPopulationsOfBreastCancer
Resistance,theirApplication
Interference,theirBeliefsRegardingCancerCausation
Restoration,theirCare
Mechanism,theirContraceptivePreferences
Cohort,theirExperiencesLivingWithSister
Susceptibility,theirHealthBehaviours
Long-term,theirLong-termSurvival
Originally,theirOriginallyTargetedPopulationsOfBreastCancer
Personal,theirOwnParticularity
Other,theirParaffin-embeddedTissues
Other,theirParticularity
Other,theirPotentialClinicalImplicationsOnBreastCancer
Collision,theirQuestionableImpactOnMortalityOnIncidenceOfAdvancedTumors
Distinct,theirRelatedMarkersAtDifferentPointsOfChemotherapyRegimensInMetastaticBreastCancer
Hazard,theirRisk
Survival,theirSurvival
Other,theirTissues
Other,them
Testing,thematicAnalysis
Other,themselves
Elusive,themVeryDifficult
Other,thenAdded
Sensitive,thenClassifiedBySupportVectorMachines
Township,thenLinkedToTownshipFemaleBreastCancerIncidenceRateIn2000s
Other,thenPresented
Values,theory
Interference,theory-basedIntervention
Other,thepresence
Caregiver,therapeuticAdvantagesParticularlyInCaseOfPremenopausalBreastCancers
Other,therapeuticEffectsInBreastCancer
Other,therapeuticSequencing
Benchmark,therapeuticTarget
Benchmark,therapeuticTargetForPotentialTreatment
Other,Therapies
Other,therapy
Therapy-related,therapy-relatedConditionsDuringBreastCancerSurvivorship
Other,therebyFrequentlyNeglected
Other,thereforeAdministered
Other,thereforeApplied
Benchmark,thereforeCentralTarget
Other,thereforeCriticalSignificance
Finding,thereforeHasAppliedToEarlyIdentification
Required,thereforeRequired
Other,theResulting
Other,They
Contribution,theyCanImpactOnQualityOfLifePresent
Other,third
Other,thirdInTermsOfSpecificMortality
Focus,third-lineTreatmentForAdvancedTriple-negativeBreastCancerthisRetrospectiveStudy
Other,This
Other,those
Other,thoseWithHr-positiveTumors
Other,thoughtfulMultidisciplinaryPlanning
Result,threeCtcsIsolatedFromOnePatient
Distinct,threeDifferentClusters
Distinct,threeDifferentUsMachines
Signature,three-lncrnaSignature
Survival,threeOverallSurvival
Evolve,threeYearsBeforeAge64Years
Survival,three-yearSurvivalRates
Other,thriceHigher
Chosen,throughOptimizationTestsChosenAsOptimalConditions
Other,thusAimed
Other,thusCritical
Mood,thusInRecentYearsDemand
Other,thusMeaningful
Benchmark,thusPotentialTherapeuticTarget
Resistance,thusWouldCrucialForApplicationOfPreventiveStrategies
Other,tightDoctor-patientCollaboration
Other,time
Other,timeInMostCountries
Discovery,timeIntervalsFromFirstDetectionToDiagnosis
Other,timeOfTheirAppointmentwithDoctor
Other,times
Purpose,time-varyingPost-diagnosisLow-doseAspirinUse
Distinct,timingOfChemotherapyForBreastCancersWithDifferentMolecularBackgrounds
Other,tissue
Biopsy,tissueBiopsy
Other,tissueDiagnosis
Other,tissueMicroarray
Other,tissues
Other,tissueStorageTime
Other,tnmStage
Conflict,toEndDevelopedWithDrugToAntibodyRatioOf329
Apatinib,tolerabilitytheApatinib
Other,tomography
Other,tool
Other,tools
Other,total
Subset,totalGroup
Distance,totalHemoglobinConcentration
Of121,totalOf121Patients
Filter,towaveletFilter
Township,township
Gene,TP53
Predictors,traditionalPredictors
Other,training
Box,transcriptionFactorForkheadBoxC1
Transcripts,Transcripts
Learning,transferLearning
Other,transport
Trastuzumab,trastuzumab
Other,trastuzumab/pertuzumab/taxane
Entry,trastuzumabInitiation
Trastuzumab,trastuzumabTherapy
Trastuzumab,trastuzumabTherapyForBreastCancer
Traumatic,traumaticBreastNeuromas
Traumatic,traumaticNeuroma
Other,treat
Other,treated
Third-line,treatedWithCapecitabineMonotherapyAsThird-lineTherapy
16,treatedWithIntraperitonealInjectionFor30Days
Testing,treatingMedicalTeam
Other,treatment
Other,treatmentMoreAccessibleToBreastCancerPatients
Other,treatmentOfBreastCancer
Description,treatmentOutcomePrediction
Other,treatmentProcesses
Protocols,treatmentProtocols
Regimens,treatmentRegimens
Treatments,treatments
Other,treatmentStrategies
Strategy,treatmentStrategy
Other,treatmentTherapy
Other,trend
Interference,tripleAssessmentFollowed
Disease,triple-negativeBreastCancer
Disease,triple-negativeBreastCancers
Subtype,triple-negativeSubtypeMda-mb-231Cells
Troponins,troponins
Other,TRPV1
Disease,tumor
Other,tumor-1
Macrophages,tumor-associatedMacrophages
Other,tumor-bearingMiceOfMcf-7BreastCancerCells
Weight,tumorBurden
Other,tumorCells
Other,tumorEasily
Finding,tumorGrowth
Finding,tumorGrowthInExperimentalModels
Other,tumorigenesisOfBreastCancer
Other,tumorigenesisOfCells
Other,tumorImaging
Provider,tumorNecrosisFactor
Other,tumorNeoangiogenesisSimilarToBreastMagneticResonanceImaging
Distance,tumorNippleDistance
Disease,tumors
Intensity,tumorSize
Advantage,tumorSizethePositivity
Allele,tumorSuppressorFunction
Allele,tumorSuppressorFunctionOfP53InPathogenesisOfBreastCancer
Allele,tumorSuppressorGene
Proportion,tumor-to-backgroundRatio
Other,tumorUptake
Disease,tumour
Disease,tumours
Spread,tumourSpread
Other,twenty-twoPatients
Mutations,twentyUniqueEsr1Mutations
Other,twoCases
Mimics,twoCasesOfMimicsOfBoneMetastasis
Platinum,twoChlorambucilPlatinum
Other,twoGroups
Other,twoImagingIndexes
Considerable,twoLargeBreastCancerDatabases
Other,twoScales
Other,two-thirdsOfBreastCancerCases
Other,twoUncommonCasesOfDelayedBreastCancerRelapses
Adulthood,twoYears
Focus,two-yearStudy
Caregiver,type
Caregiver,type160Patients
Conflict,typeOfCollisionTumor
Other,typical
Other,typicalHormone-dependentTumor
Caregiver,typicalWoman
Caregiver,typicalWoman'sDisease
Other,ultrasound
Filter,ultrasound-guidedDiffuseOpticalTomography
Testing,unbiasedRnaSequenceAnalysis
Other,unclear
Other,uncommon
Correlation,uncouplingOfInverseCorrelationBetweenBmi
Other,uncover
Other,undergoing
Other,undergone
Other,understand
Will,understanding
Will,understandingOfEmergingConceptsOfTumorBiology
Other,understood
Understudied,understudied
Understudied,understudiedPattern
Other,underutilized
Other,undiagnosed
Other,undifferentiatedNeoplasticCells
Lymphedema,unilateralBreastCancer-relatedLymphedema
Mutations,uniqueEsr1Mutations
Other,uniqueProperties
Isolation,univariableLogisticRegressionModels
Other,Univariate
Other,unknown
Other,unmetPsychosocialNeeds
Intensity,unnecessaryFollow-upVisitsForWomenWithVeryLowRisks
Other,unusual
Caregiver,unusualCaseOfPtosis
Other,upregulated
Other,up-regulated
Other,uptake
Other,urgent
Other,urgentClinicalProblem
Urgent,urgentCytology
Contribution,urgentlyAdvanceImplementation
Other,urgentlyDeveloped
Required,urgentlyNeeded
Other,us
Other,Use
Purpose,use
Utilized,used
Other,useful
Other,usefulness
Users,users
US,usExaminations
Other,Using
US,usStandardization
Restoration,usualCare
Other,usuallyAssociated
Other,utility
Other,Utilization
Utilized,utilized
Validation,Validation
Intensity,value
Values,values
Gene,VAP-1
Ecchymosis,vap-1Expression
VAP-1,vap-1ImmunohistochemicalStaining
VAP-1,vap-1NegativeStaining
VAP-1,vap-1Staining
VAP-1,vap-1StainingResults
Necessity,variableMolecularMechanismsOfCarcinogenesis
Other,variables
Mood,variablesPredictiveOfNippleAreolaComplexInvolvementInPatients
Variants,variants
Other,variousArtifactsIntroducedDuringSlidePreparation
Fertility,variousCellularProcessesCellCycleRegulation
Other,variousEnvironments
Other,variousImportantFunctions
Limitations,variousLimitationsIncludingToxicity
Various,variousMethods
Other,variousNon-pharmacologicalAdjuvantTherapies
Entry,variousOtherCancerInHumanBody
Other,variousRadiologicalChangesLeadingToDiagnosticChallenges
Gene,vascularAdhesionProtein-1
Gene,VEGF-D
Mood,veryComplexDisease
Other,veryHeterogeneousDisease
Caregiver,veryRareCaseOfTraumaticBreastNeuroma
Chosen,veryRareClinicalEntityWithOnlyFewCasesHavingReportedToDate
V-G,v-gCalciumChannelBindingAntibodies
Other,virtualReality
Other,virtualRecombinedImagesFromLeImages
Other,visits
Other,visualizedTheranosticsOfTumors
Other,vital
Purpose,vitalRole
Other,vitalRoles
Intensity,volume
Other,volumes
Vulnerability,vulnerability
Water,water
Other,wavelengthConsistencyIndex
Other,We
Other,weak
Robust,weakToStrongReactivityToOtherCellLines
Coefficient,weight
Other,well-established
Other,WES
Other,westernBlot
Other,westernBlotAnalyses
Testing,westernBlotAnalysis
Other,westernizedCountries
Adult,whenActiveUse
Basis,whenGiven
Susceptibility,whenIntegratedWithinCountry/region'sHealthPlan
Other,whenonlyAnalyzed
Other,whenSuspected
Other,whereDeveloped
Other,whereFacilitatedBySurfaceModificationOfNps
WHI,WHI
Weight,whole-tumorSamplingOfDiseaseBurden
Restoration,widelyAcceptedAsStandardOfCareFollowingBreastConservation
Other,widelyExpressed
Utilized,widelyUtilized
Advantage,widespreadInterest
Distinct,willDifferent
Distinct,willDifferentRegardingSubtypeAtDiagnosis
Testing,willLeadToMortalityReductionsWithoutUsualScreeningHarms
Purpose,willTested
Purpose,willTestedThroughEuropeanMyPersonalBreastScreening
Purpose,willUsed
Purpose,willUsedAsReferences
Other,Wilm
Delays,withandControllingForTreatmentDelays
Interference,withBetterDrugDeliveryPotentialOfNon-sphericalShapesHaveRecentlyInvestigated
Restoration,withDevelopmentOfHigh-throughputSequencingHaveDiscoveredInTumorousTissues
Species,woman
Species,women
Global,womenInWorld
Evolve,womenOfReproductiveAge
Other,women'sCancerAccounting
Subjective,women'sPersonalGoals
Other,womenWithBreastCancer
16,womenWithG
16,womenWithMore70PercecntOfPatientsTreatedWithHormonalTherapy
Global,womenWorldwide
Subgroup,wordCloud
Other,workflowConsistingOfImmunoaffinityPurification
Global,world
Global,worldwide
Global,worldwideHighestAge-standardizedBreastCancerIncidence
Hazard,worseOutcome
Other,xenograftMice
Other,x-rayMammography
Other,year
Other,yearRfsrate
Adulthood,years
Yoga,yoga
Cohort,young
Evolve,youngAge
Other,younger
Evolve,youngerAge
Survivors,youngerBreastCancerSurvivors
Cohort,youngMalePatients
Cohort,youngMen
Cohort,youngMexicanWomen
Cohort,youngWomen
Cohort,youngWomenWithInvasiveLobularCarcinoma
Other,YS
Description,zebrafishTumorModel
Poisson,zero-inflatedPoissonRegression
Zt/g4-MMAE,Zt/g4-MMAE
Other,z-test
Bromide,=-25-diphenyltetrazoliumBromideAssay